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ABSTRACT
The twenty-first century has experienced a shift in cause of death worldwide from
communicable diseases to noncommunicable diseases. Interestingly, many of these
implicated chronic diseases, such as cancer, diabetes, and cardiovascular disease, have
been shown to be programmed in the womb. As first posited by the Barker Hypothesis,
adverse exposures in utero can increase an individual’s risk for chronic disease later in
life. Therefore, pregnancy is an opportune time for intervention to improve the health of
future generations. Studies of exposures known to negatively impact infant health, e.g.
states of overnutrition (obesity, diabetes, excess gestational weight gain) and
undernutrition (starvation, protein restriction), are critical to reveal the mechanisms of and
identify markers for developmental programming. Numerous endocrine signals including
insulin, leptin, and adiponectin have been extensively investigated during pregnancy with
aberrant effects on offspring growth and metabolic function. A novel endocrine hormone,
fibroblast growth factor 21 (FGF21), which has been recently implicated as a signal for
protein restriction, has not yet been studied for a potential role in developmental
programming of future disease. Therefore, we aimed to investigate the role of FGF21 in
pregnancy. We hypothesized FGF21 may be a nutrient sensor and a signal for fetal
nutrient insufficiency during pregnancy. In studies of healthy, pregnant women, we found
FGF21 was acutely regulated by maternal macronutrient balance. We then found in both
mice and human studies that FGF21 is elevated in response to low maternal protein
intake in pregnancy. We also showed elevated maternal FGF21 correlated with
decreased infant size in the first year of life, an outcome commonly associated with
reduced maternal protein intake in pregnancy. Finally, we used the Protein Leverage
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Hypothesis to directly test whether FGF21 is indeed a protein sensor in pregnancy and
found that FGF21 is required for the hyperphagic response to low protein intake in
pregnancy. In summary, these studies support the hypothesis that FGF21 is a protein
sensor in pregnancy. Further studies in large clinical populations including fetal growth
restriction are needed to discern whether FGF21 could be used as a marker for fetal
nutrient insufficiency in the public health setting.
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CHAPTER 1: GENERAL INTRODUCTION
1.1. DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
1.1.1. Global Health
The rise in obesity and obesity-related comorbidities is a global epidemic. In 2013,
an estimated 37% of men and 38% of women worldwide were overweight or obese (body
mass index, BMI ≥ 25kg/m2) (1). In the United States, the Centers for Disease Control
and Prevention (CDC) reported an alarming 35% of American men and 40% of American
women were obese (BMI ≥ 30kg/m2) in 2013-2014 (2). Consequently, the global
population faces higher risks for chronic disease than ever before.
With substantial medical advancements in the treatment of infectious diseases and
longer life expectancy, causes for disease and mortality are transitioning. In 2012, the
Global Burden of Disease study revealed a shift in causes of disease and morality from
communicable diseases to non-communicable diseases between 1990 to 2010 (3, 4).
Across these two decades, deaths by communicable diseases decreased by 17%
(15,859,000 in 1990 to 13,156,000 in 2010) while deaths by non-communicable diseases
increased by 30% (26,560,000 in 1990 to 34,540,000 in 2010) (5). This rise of nearly 8
million deaths indicates two out of every three deaths in 2010 were due to a noncommunicable disease. Three major contributors to this 20-year rise are: a 38% increase
in death by cancer, a 31% increase in death by cardiovascular and circulatory diseases,
and most alarming a 93% increase in death by diabetes mellitus (5). Moreover, this shift
is also attributed to a simultaneous decrease in death by diarrheal disease (-42%), lower
respiratory infections (-18%), tetanus (-78%), measles (-80%), and neonatal disorders (27%) (5).
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As individuals live longer with less communicable disease, non-communicable
diseases are increasing dramatically; particularly those caused by obesity originating from
an obesogenic environment of calorie-rich, nutrient-poor diets and reduced physical
activity. In 2010, overweight and obesity caused an estimated 3.4 million deaths and was
responsible of 3.9% of years of life lost worldwide (3). Moreover, the incidence of obesity
and obesity-related comorbidities has increased globally as demonstrated by the
aforementioned drastic increases in death by cancer, cardiovascular disease, and
diabetes mellitus (three co-morbidities of obesity) in only the last 20 years (5). Intriguingly,
one theory may partially explain the documented rise in non-communicable diseases and
introduce opportunities for invention and/or prevention to combat this rapidly growing
trend: the Developmental Origins of Health and Disease (DOHaD) Hypothesis, also
known as the Barker Hypothesis.
1.1.2. The Barker Hypothesis
The Barker Hypothesis, also referred to as the Developmental Origins of Health
and Disease (DOHaD) Hypothesis, posits that exposures during prenatal (in utero) or
early postnatal development cause permanent changes to the physiology, metabolism,
and epigenome of an individual which subsequently will affect their health and increase
risk of disease in later life (6, 7). This hypothesis is primarily accredited to the late David
Barker from his initial epidemiological studies of infant mortality/size at birth and death by
cardiovascular disease. In 1986, Barker and Osmond published a pivotal epidemiological
study of the mortality rates by geographical regions of England and Wales which revealed
a positive, geographical relationship between death rates by ischemic heart disease
during 1968-1978 and infant mortality rates approximately 50 years earlier (1921-1925)
(8). As inadequate growth in utero and in early life was a primary cause for infant mortality
2

in the 1920’s, Barker and Osmond hypothesized inadequate growth early in life left an
individual more susceptible to death by ischemic heart disease in adulthood. In 1989,
Barker and colleagues published two additional observations in support of this
hypothesis: 1) results of a study of 5,654 men born in Hertfordshire, England with
recorded birth weights and causes of death found the highest rates of death by ischemic
heart disease were in men who were smallest at birth and at one year of age (9) and, 2)
an inverse relationship between birth weight and systolic blood pressure, independent of
gestational age at birth (9) from a study of 9,921 ten-year-olds and 3,259 adults born in
Britain with recorded birth weights and blood pressure. While Barker is credited by most
for founding the DOHaD field, ten years prior to Barker’s initial observations, Ravelli et al.
showed increased obesity in 19-year-old men who were exposed to the Dutch Famine
early in utero (first half of their mother’s pregnancy) (10). Moreover, this study showed a
timing-specific exposure effect as significantly lower obesity rates were observed if famine
exposure occurred later in utero (second half of their mother’s pregnancy). Barker and
Ravelli’s findings began what has grown into a vast field for researching and
understanding the impact of early life exposures on disease risk in adulthood. Such early
life exposures include, but are not limited to, under-nutrition, over-nutrition, malnutrition;
teratogens including pollutants, drugs, alcohol, etc.; altered hormonal milieus resulting
from maternal overweight, obesity, excess gestational weight gain, diabetes mellitus;
maternal stress; oxidative stress from hypertension or placenta insufficiencies.
Thus far, evidence in support of the DOHaD hypothesis has been demonstrated
through epidemiological, prospective, and interventional studies in animal models and
humans. Early epidemiological work identified the relationship between intrauterine
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exposures such as undernutrition or famine and development of disease including obesity
(11, 12) and coronary heart disease (9, 13) in adulthood. Follow up studies have further
characterized low birth weight (considered as a result of early life adverse exposure) to
be a risk factor for adult chronic diseases, including impaired glucose tolerance,
hypertension, cardiovascular disease and obesity (14-17). For example, a prospective
study of 468 men born in Hertfordshire, England with known birth weights and glucose
tolerance measured in adulthood (between 59 and 70 years old) found adult blood
pressure and glucose tolerance measurements rose as birth weights fell (15). Other
epidemiological and prospective studies of cohorts such as those in Uppsala, Sweden,
Helsinki, Finland, and the Nurse’s Health Study, USA have also revealed correlations
between small size at birth and the development of diabetes (18-23), cardiovascular
disease (24-32), unfavorable alterations in body composition (33, 34), and hypertension
(35, 36) later in life. Yet, while the observed association between low birth weight and
adult chronic disease has been reproduced in many cohorts around the world, this
supportive evidence for the DOHaD hypothesis relies heavily on the assumption that
infant growth/size at birth is an indicator of adverse exposures in utero. Addressing this
weakness, the DOHaD has also been supported by epidemiological studies in
populations with known rather than assumed exposures, as documented in Ravelli’s
study (10). For instance, studies of individuals exposed to the Dutch Famine in utero
between December 1944 and April 1945, when the daily ration for adults was 400-800
calories, have observed direct relationships between famine exposure in utero (resulting
in low birth weights) and the development of diabetes (37), high blood pressure (38), and
unfavorable body composition (39) in the offspring later in life.
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More recently, the ability of researchers to obtain longitudinal data from individuals
within large cohort studies with known in utero exposures has proven to substantially
advance the field. Data collected in addition to the important timing of conception include
biospecimens allowing for the study of epigenetics (40, 41) and prospective assessments
of body composition, blood pressure, cardiovascular risk factors, food intake, medical
history and glucose tolerance. The Quebec Ice Storm, that occurred in 1998 and led to a
loss of electrical power for up to 6 weeks in 1,400,000 households, provided a unique
opportunity for longitudinal data collection from offspring of a known in utero exposure,
i.e. objective and/or subjective maternal stress (42). Offspring of mothers who were
pregnant during the ice storm have been studied extensively throughout life and have
been shown to have adverse changes in growth and metabolism. These changes
included smaller birth size (43), increased obesity in adolescence (44), increased insulin
secretion (45), increased DNA methylation (46), and altered mental capacities with
reduced IQs (47), lower motor scores (48), and higher Autism Spectrum scores (49).
Observational and interventional clinical trials of populations experiencing adverse
intrauterine exposures also contribute to the understanding of developmental
programming. Gambian women have been part of such research because The Gambia
experiences two agricultural and thus nutritional seasons annually; the rainy (hungry)
season and the dry (harvest) season, leading to fluctuation in nutritional status. Research
groups have established relationships with communities in The Gambia, and clinical trials
to study the effects of nutritional status in this population (50) particularly in childbearing
women. These studies have been ongoing since the 1970’s. Finally, use of animal models
permit induction of exposures during gestation (which would be unethical in humans)
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allowing human intrauterine exposures and subsequent investigations of causative
mechanisms to be tested. Various species, including mice, rats, guinea pigs, sheep, and
non-human primates, have been used and their advantages and disadvantages are
eloquently reviewed by Rabadan-Diehl and Nathanielsz (51). The totality of all the above
mentioned models, epidemiological, longitudinal, observational, interventional, and
animal studies, has allowed for investigation and the forward progress of the DOHaD field
over the past 30 years.
1.1.3. Mechanistic Application of the Barker Hypothesis
The epidemiological and prospective studies supporting the DOHaD hypothesis
have spurred investigations into causative mechanisms to explain how exposures in utero
translate into permanent physiological changes in offspring. From these investigations,
the genesis of the maternal-placental-fetal communication field of study has
demonstrated cause-and-effect relationships between maternal circulatory factors and
fetal outcomes.

For example, maternal nutrient availability is a classic example of

maternal-placental-fetal communication, as extensively studied and reviewed by Powell
and Jansson (52). Conditions of nutrient scarcity or excess in the maternal circulation,
such as hyperglycemia or amino acid deficiency, have been shown to correlate with
alterations in respective placental nutrient transporter expression and activity, e.g.
placenta of mothers with hyperglycemia express higher levels of glucose transporters
compared to normoglycemic placentas. Consequently, these alterations in placenta
nutrient transport coincide with the subsequently observed fetal over- and undergrowth
respectively (52). Another example of this maternal-placental-fetal communication is the
role of the maternal circulatory factor adiponectin in the fetal overgrowth phenotype
observed with obese pregnancies. Adiponectin, a beneficial adipokine that acts as an
6

insulin sensitizer to improve glucose clearance, is elevated in healthy individuals and
found to be reduced with overweight or obesity (53-55), including in the pregnant
population (56-59). An elegant study by Aye et al. demonstrated a direct cause-and-effect
role for maternal adiponectin in the overgrowth phenotype typical of offspring of obese
pregnancies (60). Typically, in diet-induced obesity (DIO) C57BL/6 pregnancies maternal
adiponectin concentrations are decreased and placental signaling (insulin and mTORC1)
is increased leading to up regulation of placenta nutrient transport and subsequently fetal
overgrowth. Investigators rescued this fetal overgrowth phenotype by replacing the
reduced circulating adiponectin by adiponectin infusion. This in turn reversed the increase
in placental signaling and nutrient transport and corrected the overgrowth phenotype of
the offspring (60). This study exemplifies the capacity of the maternally cultivated
intrauterine environment to directly impact fetal development. However, innumerable
maternal factors are differentially regulated in and by pregnancy, e.g. hormones, blood
flow, energy balance, stress, etc., and only with in-pregnancy studies can their role as
mediators of the DOHaD hypothesis be elucidated. Undoubtedly, these examples should
provide rationale for continued investigations into the role of maternal nutritional and
endocrine factors as mechanisms of the “developmental programming” posited by the
DOHaD hypothesis.
In summary, with the current rates of obesity and obesity related co-morbidities,
our population is being conceived and developing within increasingly adverse intrauterine
environments. Considering the extensive supporting evidence for the DOHaD hypothesis,
this progressively hostile in utero development is contributing to the increased incidence
of non-communicable diseases currently observed in adults worldwide. Indeed, three of
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the largest contributors to the increase in non-communicable disease mortality are
cancer, cardiovascular disease, and diabetes mellitus; and each of these chronic
diseases have been repeatedly shown in human and animal studies to be “programmed”
in adulthood by adverse exposures in utero. As chronic disease continues to increase
and people continue to reproduce, future generations will not only develop within adverse
intrauterine environments but grow in postnatal environments that provide continued
exposures for metabolic disease. In turn, offspring will likely show evidence of chronic
diseases earlier in life and as adults, will then conceive and program the subsequent
generation with potentially increasingly hostile intrauterine environments. The cyclical
pattern of programmed chronic disease across generations epitomizes the importance
for studying the DOHaD hypothesis. Increasing our understanding of the mechanisms
that transmit these increased chronic disease risks could allow for proactive intervention
in adulthood of exposed offspring, as well as preventive intervention during pregnancy.
1.2. FIBROBLAST GROWTH FACTOR 21
Fibroblast growth factor 21 (FGF21) is a 19kDa, 209 amino acid long peptide
produced by the liver, white and brown adipose tissue, muscle (smooth and skeletal),
thymus, and endocrine and exocrine pancreas in humans. FGF21 is a member of the
“endocrine” subgroup of the fibroblast growth factor family, along with FGF19 and FGF23,
grouped together based on their similar structural homology and ability for endocrine
action. FGF21 was discovered in 2000 and reported as a potential novel therapeutic for
obesity and improved glucose and lipid regulation in 2005. Since that time, great effort
has been expended to elucidate the metabolic effects of FGF21 at the molecular and
whole-body level, to identify its mechanism(s) of action, and explore its therapeutic
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potential. As a result, publications relating to FGF21 have increased nearly exponentially
each year since 2005 (61) (Figure 1.1).
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Figure 1.1 FGF21 publications from 2000 to 2015. “Results by Year” exported from
PubMed.gov searched with title keywords: “FGF21”, “FGF-21”, and “Fibroblast growth
factor 21” (accessed December 8, 2016).
However, the research in the past decade has produced a complex and conflicting
body of literature, and thus, herein is a comprehensive summary of the current
understandings of FGF21, its capabilities, and suggested reasoning for conflicting results.
The overview will first describe the discovery of FGF21 which has shaped the subsequent
decade of research. Next, to better elucidate the physiological role of FGF21, crosssectional observations of FGF21 concentrations among various populations, phenotypes
of mouse models overexpressing or lacking FGF21, as well as effects of pharmacological
administration in animal models and humans will be presented. Finally, to better
understand the actions of FGF21, a description of the induction and regulation of this
novel hormone and tissue specific effects and mechanisms of action observed thus far
will be presented.
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1.2.1. Discovery
FGF21 was first identified in 2000 by Nishimura and colleagues from isolated
cDNA of mouse embryo (62). Murine FGF21 has 75% homology with human FGF21 and
35% homology with human FGF19. At the time of its identification, FGF21 was reported
to be preferentially expressed by the liver (62). Five years later, FGF21 was revealed to
have an adipocyte-specific glucose sensitizing capability (63). In this initial study, FGF21
induced glucose uptake in vitro in 3T3-L1 adipocytes and primary human adipocytes, an
action that was both insulin independent and additive (63). When administered to obese
rodents (ob/ob mice, db/db mice, and obese Zucker diabetic fatty (ZDF) rats), FGF21
reduced plasma triglycerides, decreased fasting insulin, and improved glucose clearance
in vivo. Investigators also developed a transgenic mouse model that overexpressed
human FGF21 using the apoE promoter (63). At maturity (9 months), the FGF21
transgenic mice showed decreased body weight, decreased hepatic lipid, and increased
brown adipose tissue, as well as decreased fastenot sud glucose and improved glucose
clearance and insulin sensitivity compared to age matched, wild type mice. On high-fat,
high-carbohydrate diets, FGF21 transgenic mice were resistant to diet-induced obesity.
Notably, the plasma concentration of FGF21 in a healthy wild type mouse is
approximately 1 ng/mL while in this transgenic strain the plasma concentration is 70-150
ng/mL. Although these results are very interesting, the physiological relevance of these
observations is not clear.
Important considerations when contemplating the therapeutic potential of FGF21
have also been assessed. Investigators evaluated the mitogenic effects of FGF21 by
treating cells in culture, including murine, nonhuman primate, and primary human cell
lines, with FGF21 and showed treatment did not induce cell proliferation. Moreover, a
10

concern of any glucose sensitizing therapeutic is its ability to induce hypoglycemia,
though no evidence of hypoglycemia in the fed or fasted state following FGF21
administration was observed in obese and lean ZDF rats. To investigate mechanism(s)
of action of FGF21, Kharitonenkov et al. observed glucose sensitizing effects of FGF21
were greatly diminished with cycloheximide treatment, leading to the postulation that the
mode(s) of action requires transcriptional/translational activation (63). Consequently,
treatment with FGF21 was found to increase GLUT1 expression (mRNA and protein) in
white adipose tissue in vitro and in vivo and induce phosphorylation of MAPK through
FRS-2 in 3T3-L1 adipocytes (63). In summary, this initial publication showed FGF21 plays
a role as a metabolic regulator affecting glucose and lipid metabolism in vitro and when
overexpressed or administered in vivo has both genomic and non-genomic actions on
adipose tissue.
1.2.2. Physiological Role of FGF21
FGF21 in the Population: The first observation of FGF21 in humans was described
in patients with type 2 diabetes mellitus (T2DM) (64). Paradoxical to its glucose and lipid
regulatory effects, plasma FGF21 was increased in patients with diabetes compared to
non-diabetic controls. Following that report, elevated serum FGF21 was observed in
overweight and obese patients compared to lean controls and positively correlated with
risk of metabolic syndrome, adiposity, fasting insulin, and triglycerides (n=232) (65).
Investigators also found FGF21 expression in subcutaneous adipose tissue correlated
with serum FGF21 in a subset of this population (n=29), giving rise to FGF21 as an
adipokine. Introducing more complexity, Galman et al. reported that circulating FGF21
varied nearly 250-fold (454 ± 799 pg/mL) within a broad human population of 76 healthy
males and females and failed to find relationships between FGF21 and BMI, lipids, or
11

plasma glucose (66). Since these early publications, FGF21 has been consistently
observed to be elevated in patients with type 2 diabetes mellitus, dysregulated glucose
homeostasis, adiposity, and an adverse metabolic phenotype (Table 1.1).

Indeed,

prospective, population-based studies across 5-years of observation have shown that
FGF21 is a predictor of the development of metabolic syndrome [odds ratio 2.6 (67)], type
2 diabetes mellitus [odds ratio 1.8 (68)] and obesity [odds ratio 2.4 (67)].
Table 1.1 FGF21 trends in clinical populations
FGF21 Trend
(compared to healthy population)
Reduced

Elevated

No change

Population
Type 1 diabetes mellitus (69)
Latent autoimmune diabetes (69)
Type 2 diabetes mellitus (64, 68-74)
Overweight/Obesity (65, 70, 72, 75-78)
Gestational Diabetes Mellitus(79, 80)
NAFLD/NASH (75, 81)
Coronary heart disease (74)
Polycystic ovary syndrome (82)
Chronic kidney disease (83)
Overweight/Obesity (84)
Gestational Diabetes Mellitus (85, 86)
Preeclampsia (78)

Apart from clinical conditions summarized in Table 1.1, FGF21 is correlated with
independent adverse markers of metabolic health, e.g. hyperinsulinemia, hyperglycemia,
and hypertriglyceridemia (Table 1.2). These observations suggest obesity and its comorbidities may induce a state of FGF21 resistance, similar to hyperinsulinemia or
hyperleptinemia. Indeed, elevated FGF21 concentrations in ob/ob, db/db, and dietinduced obese (DIO) mice have been repeatedly reported (65, 87, 88).

12

Table 1.2 Correlation of FGF21 with markers of metabolic health
FGF21 Correlation
Glucose Homeostasis
Positive correlation
Negative correlation
No correlation

Parameter
Fasting insulin (65, 71, 73, 74, 77)
Fasting glucose (70, 71, 74)
HbA1c (71, 73)
HOMA-IR (71, 73, 74, 77, 78, 85)
Glucose tolerance (70, 89)
Insulin sensitivity (70)
Fasting insulin (84)
Fasting glucose (84)
Insulin sensitivity (89)
Insulin secretion (89)

Lipid homeostasis
Adiposity (65, 77, 89)
Positive correlation
Triglycerides (65, 74, 80, 85, 89)
Total cholesterol (84, 89)
HDL (65, 74, 85)
Negative correlation
Adiponectin (77, 80, 85)
No correlation
HDL (84)
*Determined by hyperinsulinemic euglycemic clamp
Considered together, it could be suggested that the patterns of FGF21 observed
in the metabolically unhealthy clinical populations cited in Table 1.1 are likely due to the
imbalance of the metabolic markers that commonly accompany the clinical conditions
cited in Table 1.2. In other words, FGF21 is not likely a product of obesity or type 2
diabetes but rather a product of the elevated triglycerides or glucose created by these
pathological conditions.
Phenotypes of Transgenic FGF21 Mouse Models: A powerful method to better
understand the function of a hormone is to create transgenic mouse models with the goal
to either overexpress or reduce the hormone of interest in vivo. Multiple FGF21 transgenic
mouse models have been developed over the past decade and their phenotypes are
described below. As discussed earlier, transgenic FGF21-overexpressing mice (FGF21TGA) exhibit a >50-fold increase in circulating FGF21 compared to control mice. FGF21
13

transgenics are leaner than wild type controls, have increased brown adipose tissue,
reduced subcutaneous adipocyte cell size, and are resistant to diet induced obesity (63).
Furthermore, these mice have reduced fasting glucose levels, increased insulin
sensitivity, and improved glucose clearance (63). A separate transgenic line (FGF21-TGB)
generated by Steve Kliewer’s laboratory exhibit a more modest, 5-fold elevation of plasma
FGF21 and has been phenotyped extensively (90-93). Similar to the FGF21-TGA strain,
the FGF21-TGB mice are smaller than wild-type controls, though they exhibit increased
adiposity and food intake normalized to body weight, suggesting FGF21 inhibits growth
without inducing hypophagia. FGF21-TGB mice have an extended lifespan (69) and show
a metabolic profile similar to the FGF21-TGA strain, including decreased serum glucose,
insulin, triglycerides, and cholesterol, and decreased hepatic lipid. Considered together,
FGF21-TG mice appear to exhibit a phenotype mimicking long term fasting: elevated free
fatty acids (accompanied by elevated white adipose tissue lipase protein expression) and
β-hydroxybutyrate in fed conditions, increased ketogenesis, impaired glycogenolysis and
increased hepatic glycogen content. Moreover, during extended fasting, the FGF21-TG
mice show reductions in physical activity and body temperature, and enhanced torpor
compared to wild-type controls (90, 92). The phenotype(s) resulting from transgenic
FGF21 overexpression illuminate a role for FGF21 in metabolic regulation, however these
findings do not appear to be in agreement with the trends of FGF21 observed in the
human population. It is intriguing to consider that in a transgenic animal model of elevated
FGF21 that FGF21 appears to be responsible for lowering many of the adverse metabolic
markers it is positively associated with in humans, e.g. glucose, insulin, triglycerides.
Moreover, when considering evidence that FGF21 is highly variable in studies of healthy
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participants (66), perhaps the role and regulation of FGF21 is reliant and complicated by
energy and macronutrient status.
Notably, these transgenic strains have also revealed various untoward effects of
FGF21. First, consistent with their reduced size, adverse effects from FGF21
overexpression is bone loss (93) and growth hormone resistance (94). FGF21-TGB mice
show decreased bone lengths and significant decreases in bone mass (bone mineral
density, bone volume/tissue volume, bone surface, trabecular number and thickness)
(93). Induction of growth hormone (GH) resistance is also a proposed adverse effect of
FGF21 overexpression. FGF21-TGB mice show elevated levels of GH but decreased
circulating insulin-like growth factor-1 (IGF-1), a finding consistent with their small size.
Finally, female FGF21-TG mice were shown to be infertile through hypothalamic-pituitaryovarian axis responses similar to those induced by starvation (94). However, recent
findings have shown this infertility may be driven by energy balance because it was shown
to be restored with a high fat diet (95). These adverse effects should be taken into
consideration when contemplating future applications for FGF21 as a pharmaceutical
agent.
While the gain-of-function strains demonstrate a fairly consistent role of FGF21 as
a metabolic regulator, loss-of-function models are less cohesive. The first loss-of-function
model, using an adenoviral-mediated FGF21 knockdown (KD), found mice fed a
ketogenic diet with a 72% knock-down of FGF21 displayed a dysfunctional lipid
phenotype: increased serum cholesterol, triglycerides and non-esterified fatty acids
(NEFAs), elevated hepatic lipid, and reduced hepatic ketogenic-related gene expression
(96). A global FGF21 knock out (FGF21-KOA) mouse confirmed these findings (97).
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FGF21-KOA mice have normal fasting and fed glucose and insulin levels but display
impaired glucose homeostasis in response to a glucose tolerance test compared to wildtype mice. When challenged by a ketogenic diet, FGF21-KOA mice exhibit increased
weight gain and decreased physical activity; increased leptin, triglycerides, insulin, and
glucose; as well as decreased ketosis and elevated hepatic glycogen content and
hepatosteatosis (2-fold increase hepatic lipid) compared to wild-type mice also fed a
ketogenic diet. In contrast to the lean, DIO-resistant phenotype of the FGF21-TG, these
FGF21-null mice have increased body weight, lean mass, fat mass, and food intake with
age, as well as an altered adipose phenotype with increased adipocyte cell size,
decreased WAT expression of lipolytic genes, and increased BAT lipid stores. FGF21KOA mice also show attenuated weight loss following a 24hr fast, indicating mice without
FGF21 have an inefficient ability to mobilize energy.
The FGF21-KOB developed by Potthoff and colleagues replicated some of the
abovementioned findings (92). Compared to wild-type controls, the FGF21-KOB
transgenic model exhibited reduced fasting glucose, elevations in triglycerides and nonesterified fatty acids (NEFAs) in the fasted state, elevated ketones in the fed state, as well
as impaired ketogenesis. These mice did not differ in weight or fed glucose, insulin,
triglycerides, or NEFA levels, from wild-type controls. Further studies showed a reduction
in expression of key hepatic genes responsible for regulation of hepatic glucose and lipid
metabolism in response to fasting in FGF21-KOB versus wild-type mice. Complementing
the loss of bone mass observed in FGF21-TGB mice, FGF21-KOB mice have high bone
mass (93).
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Table 1.3 Summary of FGF21 transgenic mouse models
FGF21 Model
FGF21-TGA
Kharitonenkov
(63)

FGF21-TGB
Inagaki (90)

FGF21-KD
Badman (96)

A

FGF21 Levels
70-150 ng/mL

20 ng/mL

Undetectable
on standard
chow,
Decreased
72% on
ketogenic diet

FGF21-KO
Badman (97)

Undetectable

FGF21-KOB
Potthoff (92)

Undetectable

FGF21-KOC
Hotta (98)

Undetectable

Phenotype
↓ body weight/size
↓ fasting glucose
↑ insulin sensitivity
↓ body weight/size
↑ food intake
↑ fat mass
↑ lifespan
↓ glucose (fasting)
↓ triglycerides (fasting)
↓ cholesterol
↑ FFA (fed)
↑ β-hydroxybutyrate (fed)
↑ gluconeogenesis (fed)
↑ ketogenesis
↑ body weight
↑ fat mass
↑ lean mass
↓ glucose tolerance
X fasting response
- body weight
↓ fasting glucose
↑ ketones (fed state)
X ketogenesis
↑ body weight
↑/↓ fat massC
↑ bone mass
↑ lean mass
↑ adipocyte hypertrophy
↓ adipocyte lipolysis (fed)
↓ NEFAs (fed)
↑ adipocyte lipolysis
(fasted)
↑ NEFAs (fasted)

X = dysregulated or dysfunctional, c = conflicting reports

Method
-C57BL/6 background
-Gene: human FGF21
-Promoter: ApoE
-Primary source: liver
-C57BL/6 background
-Gene: murine FGF21
-Promoter: ApoE
-Primary source: liver

C57BL/6 injected with
shFGF21 or control
adenovirus

-Targeted deletion of 3′
part of exon 1, all of exon
2, and the 5′ region of
exon 3.
-FGF21loxP x Meox-cre
deletion

-Targeted deletion:
majority of exon 1 and all
of exons 2 and 3 of Fgf21
were replaced with the
IRES-LacZ-polyA/PGKneo cassette (606 of 630
bases)

A third global FGF21-KOC strain generated by Hotta et al. does not replicate the
impaired hepatic ketogenesis or lipid metabolism that had been previously observed (98).
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However, the FGF21-KOC mice show impairments in adipose tissue lipolysis. FGF21KOC mice show decreased adipocyte lipolysis and decreased circulating NEFAs in the
fed state and vice versa in the fasted state, indicating FGF21 plays a role in regulating
lipolysis (stimulating lipolysis during feeding and inhibiting lipolysis during fasting).
Studies of these loss-of-function models contribute to our understanding of the role
and regulation of FGF21, particularly when considered alongside the previously described
overexpressing models and human population trends. Taken together, these gain- and
loss-of-function models show FGF21 plays a role in regulation of metabolic processes,
particularly in response to fasting, such as ketogenesis, lipolysis (hepatic fat oxidation),
and physical activity. It also appears FGF21 is required for maximal hepatic lipid oxidation
and ketogenesis induced by a ketogenic diet. Notably, the phenotypes of the three
knockout models are much less cohesive compared to the reproducible findings across
the transgenic strains. Moreover, the findings from transgenic overexpression of FGF21
are not consistently inversely reproduced as may be expected. However, the variability in
reports of whole-body effects from a lack of FGF21 lead to important considerations for
FGF21 biology. First, cause-and-effect conclusions in loss-of-function experiments can
be more difficult to come to because whole-body physiology demands a rigorous
redundancy built into life sustaining processes. If the role of FGF21 is considered be a
metabolic regulator, it is biologically unreasonable to expect for it to be the sole hormone
responsible for effects observed in the transgenic mice, e.g. glucose metabolism, lipid
metabolism, energy expenditure regulation, etc. Second, many of the phenotypic effects
observed in FGF21-KO mice only resulted from studies of “challenged” mice, i.e. mice on
ketogenic diets, extended fasts, or advanced age. This is an intriguing observation when
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considering the disparities between effects of elevated FGF21 in healthy, transgenic
mouse stains and in metabolically unhealthy human populations. Perhaps, the differential
roles and regulation of FGF21 described in “challenged”, i.e. unhealthy, versus healthy
populations indicate various responsibilities and responses of FGF21 which are reliant on
health status.
Effects of FGF21 Administration: Another useful model for elucidating the effects
of an endocrine hormone is exogenous administration in vivo. The response to
recombinant FGF21 administered in acute and chronic protocols has been observed in
healthy, obese, and diabetic rodents, as well as in obese/diabetic non-human primates,
and most recently in humans with obesity and diabetes. These findings are collated and
summarized below (Table 1.4). As soon as two days following FGF21 administration
(measured up to 8 weeks of continuous FGF21 infusion) to rodent models of diabetes
and obesity (db/db mice, ob/ob mice, DIO mice, and ZDF rats), animals displayed
decreased fasting and fed glucose, fasting insulin, and triglycerides, improvements in
glucose tolerance and hepatosteatosis, and increases in energy expenditure (Table 1.4).
Similarly, in non-human primates, FGF21 administration decreased fasting glucose,
triglycerides, LDL-cholesterol, and body weight while increasing HDL-cholesterol.
Interestingly, neonatal pups administered FGF21 show increased expression of
thermogenic genes in BAT and increased body temperature (99). These observations
were supported by elevated thermogenic gene expression (UCP1, DIO2) in BAT and
even more so in iWAT of C57BL/6 adult mice (100). Proposed mechanisms accounting
for these metabolic improvements observed with exogenous FGF21 administration
include: upregulation of GLUT1 expression in WAT shown in in vitro and in vivo studies
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(63), induction of adiponectin (101), increased insulin production, and altered expression
of key genes involved in ketogenesis, lipid metabolism, and gluconeogenesis (See Action
of FGF21 section below) (decreases in ACC1, ACC2, SCD1, GPAT, FAS, nuclear
SREBP-1, PPARγ, ap2, CD36; increases in G6Pase, PEPCK, PGC1α, AMPKα1, CPT1α,
CPT1β, FoxA2, BDH1, UPC2; no change in DGAT1, CPT1, LPAAT, PGC1α) (102-106).
Table 1.4: Effects of FGF21 administration in animal models and humans
Healthy
rodents
Decreased
fasting glucose
Decreased
fasting insulin
Decreased fed
glucose
Improved
glucose
tolerance/Si
Decreased
lipids*
Body weight
improvement**
Improved
cholesterol***
Improved liver
health****
Increased EE

(105)

Obese/diabetic
rodents

Diabetic
nonhuman
primates

Humans
with
diabetes

(63, 102-104, 107110)

(111)

(103, 104, 107-109)

(108, 111)

(112)

(107, 110)
(108,
110)

(103, 104, 106-108,
110)

(105)

(63, 103, 104)

(108, 111)

(112)

(106,
108)

(102, 104, 106-109)

(108, 111)

(112)

(104, 108, 109)

(111)

(112)

(102, 104, 107)

(102, 104, 106,
109)
Si= insulin sensitivity, EE= energy expenditure
*triglycerides, FFAs, or NEFAs **Reduction in body weight or resistance to DIO
weight gain; ***decrease in total cholesterol, LDL, or VLDL; or increase in HDL;
****reduction in hepatic lipid, hepatosteatosis
(106)

In summary, FGF21 administration has been demonstrated to improve body
weight status, regulate lipid and glucose homeostasis, and increase energy expenditure
in diabetic and obese rodent models (ob/ob mice, db/db mice, DIO mice, ZDR) as well as
non-human primates and humans with obesity and/or diabetes. Furthermore, some of
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these effects, e.g. decreased insulin, improved glucose tolerance, weight loss, and
increased energy expenditure, have been demonstrated in healthy, lean mice as well.
Notably, while effects of exogenous administration can illuminate the role(s) of a
hormone, it is important to remain skeptical of the physiological relevance at
pharmacological doses. It is encouraging however that these administration studies
reproduced several effects of FGF21 observed in studies of transgenic, overexpressing
mice. Finally, the differential effects of FGF21 administration in unhealthy, obese or
diabetic models compared to healthy models further supports the observations in the
transgenic, knockout, and population trend studies that the role and regulation of FGF21
may be reliant on energy or macronutrient status.
1.2.3. Regulation of FGF21
FGF21 is produced by the liver (62, 113-115), white adipose tissue (65, 113, 116),
brown adipose tissue (113, 117, 118), muscle (119), and the endocrine and exocrine
pancreas (113, 120, 121). An elegant study by Markan et al. employed a liver specific
FGF21 knockout mouse model (FGF21fl/fl;Albumin-Cre) to show the liver is the primary source
of circulating FGF21 in vivo (115). Both fasting and refeeding studies in these FGF21
liver-specific knock out mice showed circulating FGF21 levels were abolished, despite
FGF21 mRNA expression being present in other expected tissues. Commensurate with
the numerous tissues which express FGF21, many mechanisms have been described
with regard to regulation of its expression which contributes to the complexity of FGF21
biology. The diet is the most common known regulator of FGF21. In circulation, FGF21
has been shown to be elevated in conditions of fasting (66, 115, 122), ketogenic diets
(122), amino acid deprivation or low protein diets (123-129), obesity and diabetes (88),
and cold-exposure (117). As PPARα is expected to be elevated in many of the
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abovementioned states (fasting, ketogenic diets, obesity), PPARα agonist administration
has also been shown to increase circulating FGF21 (66, 72, 122, 130). Current tissue
specific regulatory mechanisms are considered below.
Liver: In vitro studies of hepatocytes and in vivo studies of the liver have shown
FGF21 to be regulated by fasting (90, 96, 116, 122, 127, 131-133), refeeding (76, 134),
ketogenic diets (96, 122), amino acid deprivation/low protein diets (123-127), and obesity
(65, 88, 131, 135). Pregnancy has also been shown to be a time of elevated hepatic
FGF21 expression (114). Upstream hepatic molecular regulators that have been
identified thus far include PPARα (90, 96, 116, 122, 131), CREB-H (132, 136), ATF4 (125,
126), eIF2 (125), and SIRT-1 (137).
Adipose: In vitro studies of white adipocytes and in vivo studies of WAT have
shown FGF21 is regulated by fasting (122, 133), refeeding (116), ketogenic diets (116),
obesity (65, 72) and cold-exposure (100). Key upstream WAT regulators of FGF21
expression include PPARγ (65, 72, 122) and SIRT-1 (65).

In BAT, FGF21 is also

regulated by cold-exposure (100, 117, 138), and downstream of PPARα (117) and β3adrenergic stimulation (100, 117, 138). In muscle, FGF21 expression is induced by
mitochondrial stress (139, 140).
Understanding the mechanisms of a hormone’s regulation can help illuminate its
physiological role(s). It is important to consider that the two organs responsible for the
majority of FGF21 peptide found in circulation, the liver and adipose tissue, are also two
of the primary organs responsible for energy storage and mobilization, and thus energy
sensing. Considering the suggested role of FGF21 as a metabolic regulator and its
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potential sensitivity to energy status, it is logical that the production and secretion of
FGF21 would rely on these organs and variables under different provocations.
1.2.4. Actions of FGF21
FGF21 action is reliant on cell surface co-factor β-Klotho: Traditionally, fibroblast
growth factor proteins signal extracellularly through cell-surface fibroblast growth factor
receptors (FGFRs). FGFRs are ubiquitously expressed in one of four common isoforms
(FGFR1, 2, 3 and 4) (141). However, the structure of FGF21 (along with FGF19 and
FGF23) has a unique C terminus missing a binding domain other FGFs rely on to bind to
FGFRs. The absence of this binding domain disables FGF21 from binding efficiently to
FGFRs which suggests the need of additional cell surface interaction(s) for effective
FGF21 signaling. FGF21 requires a co-factor, β-Klotho, to securely bind and activate
FGFR (142). Micanovic et al. confirmed the C terminus is responsible for the interaction
between FGF21 and β-Klotho (143). This co-factor necessity confers signaling specificity
of FGF21; only tissues that express β-Klotho respond to FGF21.
In early in vitro studies, fibroblasts (cells without β-Klotho) were shown to be
unresponsive to FGF21 (144, 145), while treating Baf3 cells (cells typically without FGFRs
and Klotho isoforms) with β-Klotho and FGFR1 knock-in with FGF21 can activate FGFR1
intracellular receptor signaling (146). siRNA knock-down of β-Klotho in 3T3-L1 adipocytes
resulted in attenuation of FGF21 downstream signaling and effects (142, 147), while
FGF21-mediated improvements in metabolism are elusive in global β-Klotho knock-out
mice (109, 148). Moreover, a β-Klotho agonist (mimAb1) conferred the same beneficial
FGF21-mediated effects when administered to non-human primates (149). These
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investigators also found ablation of FGF21-mediated improvements in an FGFR1 knockout mouse model, indicating FGF21 signals primarily through the FGFR1 isoform
in conjunction with β-Klotho. Indeed, β-Klotho knock-in, knock-down, and global/tissue
specific β-Klotho knock-out models have been essential in understanding the actions of
FGF21.
Tissue Specific Actions of FGF21: As detailed above, β-Klotho expression confers
the responsiveness of a given tissue to FGF21, and tissues known to express β-Klotho
are the liver (113), white and brown adipose tissues (105, 142, 147) (113, 150),
hypothalamus (151, 152), and the exocrine and endocrine pancreas (113). The tissuespecific effects of FGF21 are organized below by tissue of action.
Adipose tissue: The currently known primary actions of FGF21 on adipose tissue
known thus far are: increased glucose uptake (63, 104), insulin sensitivity (104), energy
expenditure (99), and browning (100). Indeed, the initial breakthrough for a role of FGF21
as a metabolic regulator was in murine and human white adipocytes, where it was shown
to upregulate expression of the glucose uptake gene GLUT1 (63). Subsequently, in WAT,
FGF21 has been shown to also effect expression of genes involved in lipid metabolism
(lipogenesis and lipolysis) and browning (UCP1, DIO2, PGC1α, CIDEA Cox7a) (100, 124,
153). In vivo treatment with FGF21 in C57BL/6 mice resulted in increased UCP1-positive,
multilocular adipocytes in inguinal and perirenal adipose tissue (100). Acute and chronic
FGF21 administration also promotes sustained adiponectin secretion. In studies
employing adiponectin knock-out mice, adiponectin has been demonstrated to be a key
mediator of FGF21 benefits, such as decreased glucose levels, improved insulin
sensitivity and hepatic steatosis, and elevated energy expenditure (101, 154). In BAT,
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FGF21 increases oxygen consumption and glucose uptake and oxidation (99, 115, 148),
while regulating thermogenic and glucose uptake gene expression (UCP1, DIO2, PGC1α,
GLUT1, GLUT4, and CPT1α) (99, 100, 124, 153).
Mechanisms of FGF21 action in adipose tissue are thought to function by
autocrine, paracrine, and endocrine means (100, 116). Dutchak et al. demonstrated, in
the absence of elevated plasma FGF21, increased WAT FGF21 mRNA and protein
expression alongside the expected increase in FGF21-mediated WAT activity with TZD
administration (116). Investigators also showed in vitro TZD treatment increased FGF21
protein in culture media of white adipocytes. Initially, FGF21 was proposed to mediate its
effects through transcriptional regulation (63); however, studies with bolus FGF21
injections have shown short-term effects of FGF21 on adipocytes (within 5-60 minutes of
administration) as well (101, 104). While precise mechanisms of regulation and action
continue to be elucidated, to date FGF21 has been shown to increase FRS2 and ERK1/2
phosphorylation in adipocytes (63, 147) and induce STAT3 phosphorylation and CREB
phosphorylation (with subsequent PGC1α expression) in brown adipocytes (155). FGF21
has also been shown to be intricately interwoven with PPARγ signaling by suppressing
sumolyation of PPARγ and thereby increasing its transcriptional activity (116), however
this finding has yet to be repeated. Loss-of-function studies have revealed a critical
significance of FGF21 action on adipose tissue for the whole body. Both lipodystrophic
mice and mice without FGF21 receptors (β-Klotho or FGFR1c) in adipose tissue are
refractory to the whole-body metabolic benefits of FGF21, including decreases in body
weight, plasma glucose, insulin, and triglycerides, and improvements in glucose uptake
and insulin sensitivity (148, 155-157).
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Liver: The primary actions of FGF21 on the liver are in regulation of glucose and
lipid homeostasis. FGF21 decreases hepatic glucose output, increases ketogenesis and
fatty acid turnover while decreasing hepatic steatosis. Gain-of-function studies in
transgenic overexpressing mice and elevated-FGF21 models (e.g. fasting, ketogenic diet,
pharmacological administration) have shown FGF21 increases ketogenesis, lipid
oxidation and circulating ketones, and decreases triglycerides and cholesterol in the liver
(90, 92, 96, 104, 105). Loss-of function studies support this lipid regulation role: FGF21KO mice display reduced ketogenesis (92), β-oxidation, and increased circulating FFAs
and steatosis, while FGF21 knock-down mice exhibit fatty livers and decreased serum
ketones on a ketogenic diet (96). In studies of transgenic overexpression and
pharmacological administration in obesity, FGF21 reduces or reverses hepatic steatosis,
potentially by decreased nuclear localization of SREBP-1 and downregulation of
expression of genes involved in de novo lipogenesis (ACC1, ACC2, SCD1, GPAT, FAS,
aP2, and CD36) (92, 102, 104).
The role of FGF21 in hepatic glucose regulation is controversial. The current
consensus is that FGF21 plays a role in glucose flux, with additional roles, specifically
gluconeogenesis, still to be elucidated. Studies of pharmacological administration of
FGF21 to obese mice have consistently led to improved hepatic insulin sensitivity and
improved glucose clearance (103, 104, 106, 158).

Supporting a role for FGF21 in

stimulating gluconeogenesis, Potthoff et al. reported increased gluconeogenesis (similar
to fasted levels) in fed FGF21-transgenic mice and mild hypoglycemia in fasted FGF21KO mice which investigators suggests indicate an impairment in gluconeogenesis (92).
In support of these findings, Liang et al. also reported severe hypoglycemia and impaired
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gluconeogenesis in FGF21-KO mice (152), and Fisher et al. found elevated hepatic
gluconeogenic gene expression (glucose-6-phosphatase (G6Pase) and phosphoenol
pyruvate carboxykinase (PEPCK)) two-hours following IP FGF21 injection of healthy wildtype mice (105). However, in argument against FGF21 stimulating gluconeogenesis,
multiple studies have been unable to reproduce hypoglycemia in separately derived
FGF21-KO strains (97, 98, 159). In a recent study of the FGF21-KO strain used by
Potthoff and colleagues (92), mice were reported to show increased hepatic glucose
production and hepatic insulin resistance (160). Additionally, FGF21-KD mice on a high
fat diet exhibited a 75% increase in gluconeogenesis, accompanied by increases in
hepatic G6Pase and PEPCK expression (161). FGF21 administration studies in obese
rodents have shown a decrease in hepatic glucose production confirmed by in vitro
studies showing FGF21 suppresses glucose production in hepatocytes (104, 158, 162).
Likely stemming from studies using various pharmacological agents and different loss-offunction mouse strains, along with inconsistent energy balance statuses, the literature
available on the role of FGF21 in hepatic gluconeogenesis is contradictory and
controversial; more work is needed to better elucidate its role.
The liver shares certain mechanisms of action of FGF21 with adipose tissue.
FGF21 has been shown to induce FRS2 and ERK1/2 phosphorylation in liver as well as
adipose tissue (87, 105, 163). Hepatic PGC1α has also been demonstrated to be induced
by FGF21 (92, 105), and many genes regulated by FGF21 are targets of PPARγ and
FoxO1 (105). Many of the mechanisms of action of FGF21 in the liver however appear to
be indirect. While the above downstream signaling effect demonstrates direct FGF21
actions on the liver, hepatic β-Klotho expression is very low compared to other primary
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tissues of FGF21 action (113). Investigators have had difficulty reproducing in vivo
observations in vitro (e.g. hepatocytes, liver perfusion studies) (92, 147), and tissue
specific FGF21 receptor knockouts in the nervous system and adipose tissue have
eliminated many of the hepatic effects of FGF21 (153, 157).
Central Nervous System: FGF21 is not synthesized by the brain but can cross the
blood brain barrier in mice and humans (77, 151, 164). Considering that the
suprachiasmatic nucleus and paraventricular nucleus of the hypothalamus and the area
postrema and solitary nucleus in the hindbrain (dorsal-vagal complex) all express βKlotho, the brain has become a tissue of great interest for FGF21 action (113). Indeed,
studies employing brain specific β-Klotho-KO models (SVN-KO using Camk2a-Cre or
DVC-KO using Phox2b-Cre) have revealed significant roles for FGF21 in and/or
throughout the brain including suppression of physical activity, regulation of ketogenesis,
and modulation of certain FGF21 metabolic outcomes previously described such as
reduced body weight, bone growth, insulin, and cholesterol, and increased energy
expenditure and BAT thermogenesis (151, 153). In support of these KO models, ICV
injections in obese rats resulted in increased energy expenditure and improved insulin
sensitivity, believed to result from decreased hepatic glucose output (162). Moreover,
ablation of β-Klotho in these hypothalamic nuclei lead to differential expression of
metabolic regulatory genes in both liver and adipose tissue (Igfbp1, Pck1, Cyp2d6,
Hsd3b5, Ucp1, Dio2, Pparγ, Atgl, Hsl, Scd1, Adipoq), demonstrating the ability of FGF21
to act centrally to exert effects on peripheral tissues.
Mechanisms of action of FGF21 in/throughout the brain are less defined as liver
and adipose tissue. However, one well established conclusion is that FGF21 increases
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circulating corticosterone by increasing hypothalamic Crf expression in mice (151, 152).
Owen et al. also showed FGF21 directly increases sympathetic stimulation of BAT using
multifiber sympathetic nerve recording following ICV or IP FGF21 administration (153).
Finally, as also seen in liver and adipose tissue, FGF21 has also been shown to induce
phosphorylation of ERK1/2 in the hypothalamus (165).
Pancreas: Many of the actions of FGF21 on the pancreas remain to be revealed,
however, it is well established that this tissue produces FGF21 and expresses β-Klotho.
Demonstrated early in FGF21 research, FGF21 was shown to increase the number of
islets, number of β-cells, and insulin content within islets in the pancreas of db/db mice
and healthy rats (110), as well as regulate glucose-sensitive insulin secretion (110).
FGF21 also plays a protective role for the pancreas, as it has been shown to protect INS1e cells from apoptosis, decrease caspase activity in β-cells in studies of isolated
pancreatic islets, and reduce pancreatitis by protecting pancreatic acini from damage
(110, 120). While likely an indirect effect of FGF21 mediated improvements in lipid and
glucose regulation, it is worth noting FGF21 has been repeatedly shown to decrease
glucagon secretion (63, 103, 111). Interestingly, treatment with a glucagon receptor
agonist resulted in elevation of circulating FGF21 levels in mice and humans, suggesting
a keen interplay between FGF21 and glucagon that deserve further investigation (166).
Reviewing the differential tissue-specific roles of FGF21 underscores the
complexity of FGF21 biology. The actions of FGF21 common across tissues, particularly
organs involved in energy and substrate regulation such as the liver, adipose tissue, and
brain, emphasizes the significant role for FGF21 in metabolic regulation. In adipose
tissue, liver, and the brain, FGF21 exerts either direct or indirect effects on regulation of
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glucose metabolism, lipid handling, and the tissue’s responsiveness to insulin. FGF21
shares common effects on energy expenditure across tissues as well. Considering the
inconsistent findings within the field of FGF21 regulation (likely complicated by the health
and energy status of the employed model), mechanistic studies such as these provide
clearer evidence for cause-and-effect relationships for FGF21 action. However, studies
describing inter-organ effects (e.g. brain and BAT) serve as important reminders that
many of these highly controlled models, such as cell culture experiments, are missing this
potentially key, whole-body interplay.
1.2.5. Summary
FGF21 was initially revealed to have adipose-specific glucose sensitization
properties. Since its discovery, FGF21 has been found to play diverse roles in metabolic
regulation particularly in the liver, adipose tissues, and brain (β-Klotho expressing
tissues). Similar to insulin or leptin, FGF21 is elevated in human populations with obesity,
as well as type 2 diabetes mellitus, dysregulated glucose homeostasis, and an adverse
metabolic phenotype. Regulation of FGF21 expression and secretion varies among
tissues but overall appears to respond primarily to energy balance and nutrient intake,
e.g. fasting, ketogenic diets, low protein diets, pregnancy, cold-exposure, obesity, etc.
Gain- and loss-of-function models, as well as pharmacological administration studies,
have revealed the role of FGF21 in regulation of energy expenditure, body weight, lipid
homeostasis, glucose homeostasis, ketogenesis, lipolysis, and liver health (i.e.
ectopic lips and hepatic steatosis).
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1.3. PREGNANCY
Pregnancy is a series of physiological events which begins with the creation of an
embryo, followed by the development of a fetus, and ending with delivery of a neonate.
As reviewed in Chapter 1.1, in pregnancy the intrauterine environment fostered by a
mother can impact the development, growth, and health of her offspring. Indeed, studies
of the impact of pregnancy pathologies that can influence fetal growth, e.g. gestational
diabetes, preeclampsia, or fetal growth restriction, have revealed adverse consequences
for the long-term health of the offspring, such as cardiovascular disease, cancer,
diabetes, and obesity (9, 11-17). Moreover, studies of less abrasive exposures, such as
maternal nutrition imbalance or excess gestational weight gain, have also shown adverse
effects on offspring health such as hypertension and obesity (38, 167-169). These
findings reveal that the impact of the intrauterine environment is great, and that the
intrauterine development of the fetus may be more delicate and long-lasting than
previously thought. To better understand the contributions of the intrauterine environment
to fetal development, a brief overview of the physiology of pregnancy is outlined below
beginning with the development of the embryo/fetus, changes in the mother, and
placental development and function.
1.3.1. Fetus
In utero development can be studied in two stages: the embryonic stage and the
fetal stage. The embryonic stage begins with the release of a secondary oocyte from the
ovary (ovulation). The oocyte travels through the fallopian tube where it is entered into by
a sperm cell, eventually causing the fusion of two haploid cells and creating a single
diploid zygote. Rapid mitotic divisions occur that results in a blastocyst approximately 5
days following fertilization. The blastocyst attaches to the endometrium of the uterus
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between days 6 and 7 to establish the pregnancy. In the next week, trophoblast cells
(cells which will make up the placenta, amniotic sac, and umbilical cord) begin to
differentiate, the yolk sac is established, and the inner cell mass differentiates into the
bilaminar embryonic disc. In the third week after fertilization, the placenta and chorionic
villi begin to develop and gastrulation and neurulation occur. During the following month,
all major organs are established, albeit not yet functional, by the end of the eighth week
(organogenesis). Week 8 marks the end of the embryonic stage and the beginning of the
fetal stage. During the fetal stage, the fetus will develop for approximately 32 additional
weeks growing from an estimated 30 grams to a full-term 3400 grams as the organs
established during the embryonic stage differentiate and mature.
1.3.2. Mother
During pregnancy, many physiological changes occur in the mother to
accommodate for and support the growing fetus. A woman with a normal body mass index
(BMI) at conception is recommended to gain approximately 25-35 pounds (170). Thirtyeight percent of mass gained is due to the products of conception (fetus, placenta,
amniotic fluid), 27% due to maternal energy stores (fat mass), and the remaining 35%
can be attributed to increased blood volume and extracellular fluid, increased breast
tissue, and the enlarged uterus (171, 172). Estimations of tissue deposition in a healthy
pregnancy are 925g of protein gain and 3345g of fat gain [Table 1.5, adapted from (173)].
The energy cost of this tissue deposition is estimated to be a total of 41,518 kcal in
pregnancy. Weight gain above or below the recommended amount can lead to adverse
consequences of mother and her fetus (170).
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Table 1.5 Estimated gestational tissue depositions and respective energy costs (173)

Products of Conception
Fetus
Placenta
Fluid (amniotic + blood)
Uterus and breasts
Maternal Energy Stores
Totals

Protein Gain
(grams)

Fat gain
(grams)

Total
(calories)

440
100
138
247
0
925

440
4
20
16
3345
3825

6644
598
963
1536
31778
41519

In 2009, the Institute of Medicine (170) released updated weight gain recommendations
classified by preconception BMI. A woman entering pregnancy with a BMI between 18.5
and 24.9 kg/m2 is recommended to gain between 25 and 35 pounds, entering pregnancy
with a BMI of 25 to 29.9 kg/m2 between 15 and 25 pounds, and entering pregnancy with
a BMI greater than 30 kg/m2 between 11 and 20 pounds. The Food Nutrition Board (173)
has published energy and macronutrient recommendations during pregnancy with special
considerations for increased conservation of nutrients during pregnancy and the
increased nutrient demand of pregnancy. However, as the data available is insufficient
for determining estimated average requirements (EAR) in pregnancy, many of the intake
recommendations are based on requirements for a weight gain of 16 kg (the average
gestational weight gain reported by Carmichael et al. (174). Therefore, the recommended
energy intake for a woman between the ages of 19 and 50 years is 2403 kcal/day in the
first trimester, 2743 kcal/day in the second trimester, and 2855 kcal/day in the third
trimester. Others have created a mathematical model that can estimate individual energy
requirements for each trimester of pregnancy that can foster healthy weight gain (175).
The EAR for carbohydrate intake is 135 g/day, for fiber is 28 g/day, and for protein is 0.88
grams/kg/day. While there is not a total fat intake recommendation, 13 g/day of n-6
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polyunsaturated fatty acids and 1.4 g/day of n-3 polyunsaturated fatty acids are
recommended during pregnancy.
1.3.3. Placenta
The placenta is a transient organ present only in pregnancy that serves as a
gateway between the mother and her fetus. The placenta transports nutrients and oxygen
to the fetus and waste from the fetus, and equally as important, the placenta can prevent
transport of pathogens from the mother. The placenta is responsible for serving as the
respiratory, endocrine, immune, and gastrointestinal systems for the fetus. It is also an
endocrine organ responsible for producing hormones to be secreted into the maternal
and/or fetal circulation. Below is a detailed description of placenta invasion and
development (Table 1.6) as well as placenta transport.
Table 1.6 Placenta morphological development
Month
3
4
5
6
7
8
9
10

Placenta
Weight
30 g
70 g
120 g
190 g
260 g
320 g
400 g
470 g

Placenta
diameter
50 mm
75 mm
100 mm
125 mm
150 mm
170 mm
200 mm
220 mm

Maternal-fetal
diffusion distance
35 μm
20 μm
12 μm
10 μm
-

Total villous volume
0.3 m2
0.6 m2
1.5 m2
2.8 m2
4.0 m2
7.0 m2
10.0 m2
12.5 m2

Invasion and Development: Beginning eight days after fertilization, the trophoblast
cells develop into two layers: syncytiotrophoblast and cytotrophoblast. The function of the
syncytiotrophoblast will be to transport nutrients, gases, and waste and synthesize
hormones, while the cytotrophoblasts will serve as the progenitor cells for the placenta.
The syncytiotrophoblasts secrete enzymes that digest the endometrial cells of the uterine
lining which allows the blastocyst to become buried in the endometrium. As the
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trophoblasts erode into the decidua, the trophoblastic blastocyst cover subdivides into 3
layers: primary chorionic plate which is composed mainly of cytotrophoblasts, the lacunar
system, and the cytotrophoblast shell which is composed mainly of syncytiotrophoblasts
covering cytotrophoblasts. Fingerlike projections called chorionic villi that will contain the
fetal blood vessels begin to form. By week 3, fetal blood vessels develop in the chorionic
villi which will fully connect to the embryonic heart through the umbilical arteries and vein
by the end of 12 weeks. During weeks 4-7, fetal capillaries continue to develop within
chorionic villi which contain nucleated fetal erythrocytes. The trophoblastic shell
transforms into the basal plate hallmarked by mixing of trophoblastic and decidual cells.
By the end of week 7, feto-placental circulation is established but resistance is high and
most of the fetal erythrocytes are nucleated. There is no maternal arterial circulation to
the placenta yet. During weeks 8-12, extravillous cytotrophoblasts begin to invade and
remodel maternal uterine arteries (a process that completes about week 22) and all
chorionic villi are vascularized but only occupy 4% of the villous space. The presence of
nucleated fetal erythrocytes declines rapidly and complete feto-placental circulation is
established as well as maternal arterial circulation to the placenta. In the second trimester,
once these structures and the maternal-fetal exchange have been established, the
remaining placenta development is generally a continuation of the following processes:
development of fetal capillaries into the chorionic villi, maturation of immature villi into
immediate and stem villi, growth of villi diameter to accompany increased blood
volume/flow from fetus, cytotrophoblasts surrounding the villi are replaced by
syncytiotrophoblasts, and fibrinoid deposition begins. In the third trimester, the same
processes continue from the second trimester, however the villi mature further into
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terminal villi as well. By the end of gestation, 40% of villous volume is terminal villi and
the total villous volume is about 12.5 m2. See the table below for month-by-month details
in placenta morphological development.
Transport: The ability of the placenta to provide nutrients for the fetus relies
primarily on nutrient availability in the maternal circulation, the expression of nutrient
transporters by the placenta, and utero-placenta blood flow. Indeed, there is increasing
support to show the placenta can sense nutrient availability in the maternal circulation
and respond by up- or down-regulating nutrient transporters (52). While placental surface
area is the primary determinate for transport of permeable molecules, e.g. oxygen, the
placenta uses active and passive transport systems to transport less permeable
substrates, e.g. glucose, amino acids, and ions. The primary barrier between mother and
fetus in the placenta is a single layer of syncytiotrophoblasts. Intriguingly, these polarized
cells have differential regulation of nutrient transporters in the maternal (microvillous
membrane) versus the fetal side (basal membrane) which contributes to the regulation of
transfer and fetal nutrient availability.
The three primary macronutrients, protein, carbohydrate and fat, each cross the
placenta by independent transport systems. The most complex system is the transport of
amino acids. There are over 20 proteins responsible for amino acid transport and they
can be classified into two categories: accumulators and exchangers. The accumulators,
also called System A, co-transport non-essential, neutral amino acids into the cell with
sodium. The primary transport proteins in System A of the human placenta are SNAT1,
SNAT2 and SNAT4. The exchangers, also called System L, then use these intracellular
non-essential amino acids and exchange them to transport extracellular essential
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(aromatic or branch chained) amino acids against their concentration gradients into the
cell. The primary transport proteins in System L of the human placenta are LAT1 and
LAT2. Fatty acids are hydrolyzed from triglycerides within maternal lipoproteins primarily
by lipoprotein lipase and endothelial lipase. These fatty acids are then transported across
the syncytiotrophoblast by five fatty acid transport proteins (FATP) in the human placenta:
FATP1, FATP2, FATP3, FATP4, FATP6. Once inside the syncytiotrophoblast, fatty acids
are trafficked by four fatty acid binding proteins (FABP1, FABP3, FABP4, and FABP5) for
transport to the fetus, beta-oxidation, or esterification. Finally, the simplest nutrient
transport system is the facilitated diffusion of glucose by glucose (GLUT) transporters.
The higher concentration of maternal glucose facilitates the diffusion of glucose towards
the fetus. GLUT1 is the primary glucose transporter, however GLUT3, GLUT4, GLUT8,
GLUT9, GLUT10, and GLUT12 are also expressed in the human placenta. Interestingly,
GLUT expression in the basal membrane (fetal side) is much lower compared to the
microvillous membrane (maternal side of the syncytiotrophoblast), suggesting basal
membrane transport is the rate limiting step for transfer of glucose to the fetus. These
three systems collectively supply the primary macronutrients necessary for fetal
development and growth, and changes to these systems in response to maternal
malnutrition, maternal pathology, or placenta pathology can be highly informative for
studies of developmental programming. In summary, fetal development from an embryo
to neonate requires a highly complex and coordinated set of processes. At the heart of
these events is the placenta whose intricate functions facilitates the transfer of the
maternal environment to the growing fetus which can impact health at birth and beyond.
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1.4. PROJECT SUMMARY
Due to the enduring obesity epidemic, the global population is now heavier and
faces higher risks for chronic disease than ever before. Unfortunately, reproductive aged
women are not spared in this epidemic, and as a result the DOHaD hypothesis would
suggest our population is now participating in a deadly cycle: conceiving children within
unhealthy early-life environments (maternal overweight, obesity, diabetes, hypertension,
stress, etc.) which are “programming” the infant to herself grow up with increased risks of
these co-morbidities; subsequently, when the adversely “programmed” child reaches
reproductive age, she is more likely to present with these complications and expose her
own offspring to the very environmental offenders which contributed to her own.
Reflecting the impact of this cycle, a dramatic shift in the causes of global mortality has
been observed over the past 20 years from communicable diseases to noncommunicable diseases, such as those shown to be “programmable” through in utero
exposures. As evidence grows to show that the propensity for chronic, non-communicable
diseases can begin in the womb, so too grows the need to discover and understand the
causative mechanisms linking the intrauterine environment of an infant and his or her risk
for disease in adulthood.
One field aiming to understand the mechanisms of the DOHaD is the study of the
maternal-placental-fetal unit. Indeed, many hormones and nutrients in the maternal
circulation are altered under conditions associated with adverse developmental
programming. For example, adiponectin is decreased in pregnant women with obesity
and insulin and glucose can be increased in pregnant women with diabetes. As the
maternal circulation comes into contact with the placenta, these factors communicate to
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alter its development and activity which could subsequently affect the nutrients,
hormones, oxygen, etc. the fetus receives during development.
FGF21 is a novel endocrine hormone differentially regulated in non-pregnant
populations with conditions that are well-established offenders in adverse developmental
programming. For example, FGF21 has been shown to be elevated in individuals with
obesity, individuals with diabetes, and under conditions of malnutrition and protein
deprivation. Moreover, murine and human placenta have been demonstrated to express
FGF21 receptors (FGFR1 and β-Klotho). Taken together, the work included in this
dissertation will explore the potential role of FGF21 to act as a mediator of the DOHaD
hypothesis.

For the first time, our results describe FGF21 in a healthy, pregnant

population. We extended these observations to explore the role of FGF21 as a protein
sensor in pregnancy and a potential mechanism operating through the maternalplacental-fetal unit to impact fetal development.
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CHAPTER 2: FIBROBLAST GROWTH FACTOR 21 IN PREGNANT
WOMEN
2.1. INTRODUCTION
Fibroblast growth factor 21 (FGF21) is secreted in response to energy imbalance
for the regulation of energy and nutrient metabolism. First discovered as a glucose
sensitizer of adipose tissue, FGF21 has since been shown in both animal models and
human studies to regulate glucose and lipid metabolism under various states of energy
balance (63). Metabolically challenged transgenic models overexpressing FGF21 and
pharmacological administration of FGF21 to obese and diabetic animals and humans
have revealed FGF21 to be capable of reducing body weight, protecting against diet
induced obesity, improving glucose tolerance, and improving lipid profiles (63, 102-104,
106-112). Intriguingly, cross sectional studies of the human population show that FGF21
is elevated in clinical conditions of energy or nutrient excess, such as obesity and type 2
diabetes (64, 65, 68-78). FGF21 is also positively correlated with metabolically
unfavorable

characteristics,

such

as

hyperinsulinemia,

insulin

resistance,

hypertriglyceridemia, and total circulating cholesterol (65, 71, 73, 74, 77, 78, 80, 85, 89).
Pregnancy is a state of energy flux with energy and macronutrient demand
increasing at variable rates and in response to various cues throughout gestation.
Considering the impact of energy status and macronutrient balance on FGF21 expression
and action, understanding how FGF21 is regulated and/or acting in pregnancy could be
highly informative to FGF21 biology. However, descriptions of FGF21 in the pregnant
population are surprisingly limited to cross sectional studies in pregnant women with
gestational diabetes or preeclampsia, and the majority of these studies show FGF21 to
be elevated in these conditions (79, 80, 176-178). These reports also confirm well
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established associations between FGF21 and an untoward metabolic milieu described in
the non-pregnant state. For example, FGF21 in late pregnancy positively correlates with
triglycerides and insulin resistance and inversely with adiponectin and HDL-cholesterol
(80, 176, 177). The current knowledge of FGF21 biology in pregnancy is therefore in need
of more in depth studies in healthy populations throughout pregnancy. The aim of this
study was to describe FGF21 in a healthy population of pregnant women and to
understand the role of maternal energy stores and the placenta on FGF21 secretion. We
hypothesized FGF21 concentrations would be higher in women with increased body mass
index, adiposity, and glucose intolerance.
2.2. MATERIALS AND METHODS
2.2.1. Study population
One hundred and fourteen pregnant women enrolled in the Expecting Success
Study (n=54, NCT01610752) or the MomEE study (n=60, NCT01954342) at Pennington
Biomedical Research Center in Baton Rouge, Louisiana were potentially eligible for this
ancillary study. As detailed elsewhere, participants were recruited primarily from
obstetrical offices, augmented by print and social media advertisements (179). For entry
into a parent study, participants were required to be healthy, overweight and obese
women (BMI>25kg/m2) aged 18-40 years with a single, viable, first trimester pregnancy
(<14 weeks gestation). Medical clearance for participation was also required by a primary
care obstetrician or midwife and the Medical Investigator. Patients were excluded for
pregnancy-related conditions (known fetal anomaly, planned termination of pregnancy or
adoption of infant, history of ≥3 consecutive miscarriages), hypertension, diabetes
(diagnosis prior to pregnancy, elevated HbA1c, or first trimester OGTT diagnosis of

41

diabetes), psychological criteria (history or current psychotic disorder, current major
depressive episode, bipolar disorder, history of anorexia or bulimia, current eating
disorder, or actively suicidal), medications (metformin, systemic steroids, antipsychotic
agents, anti-seizure medications, or medications for ADHD), HIV, severe anemia,
contraindications to exercise (180), prior or planned (within one year of expected delivery)
bariatric surgery, or recent history of or current nicotine, alcohol, or drug use. Of the 114
participants in the parent studies, 43 satisfied inclusion criteria for this ancillary study,
provided consent for future use of biospecimens (i.e. blood, placenta), and had the
required clinical data available at one or more time point for analysis. Briefly, the
Expecting Success Study (NCT01610752) was an interventional study testing the efficacy
of a lifestyle intervention designed to help overweight and obese pregnant women gain
the recommended amount of weight in pregnancy. The MomEE Study (NCT01954342)
was an observational study determining energy requirements of overweight and obese
women across pregnancy. Both parent studies and this ancillary study were approved
and monitored by the Pennington Biomedical Research Center Institutional Review Board
and all participants provided verbal and written consent prior to study initiation.
2.2.2. Clinic Assessments
The parent studies enrolled women in the first trimester of pregnancy (<14 weeks
gestation) and study visits for data collection coincided with gestational age to allow for
one assessment visit per trimester, i.e. 1st trimester (<16 weeks), second trimester (2526 weeks), and third trimester (35-36 weeks). Study visits were conducted in the morning
following an overnight fast and allowed for collection of body weight, body composition,
and blood. All data were obtained in accordance with standard operating procedures of
Pennington Biomedical Research Center to ensure scientific rigor and reproducibility.
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2.2.3. Body weight and body mass index
Maternal body weight was recorded twice after a 10-hour fast with the participant
wearing a hospital gown and undergarments only. The two recorded weights were
averaged and the hospital gown weight subtracted. Body mass index was calculated as
body weight (kg) divide by the square of study-measured height (m2). Pregravid weight
was determined by self-report recorded by questionnaire and confirmed by interview.
2.2.4. Body composition
Maternal body composition was assessed by air displacement plethysmography
using a BOD POD® (COSMED). Fat mass and fat free mass were calculated from body
volume as determined by the BOD POD® with equations by van Raaij et al. (181, 182).
2.2.5. Blood chemistry
Serum glucose and insulin were assayed with the Beckman Coulter DXC 600 Pro
(Beckman Coulter Inc., Brea, CA). Fibroblast growth factor 21 was measured in duplicate
by sandwich enzyme-linked immunosorbent assay (ELISA) according to manufacturer
instructions (RD191108200R, Fibroblast Growth Factor Human ELISA, Biovendor, Brno,
Czech Republic). Serum was diluted 1:2 (125μL of serum in 125μL of dilution buffer)
before analysis. The detectable concentration by the assay is 0.03 ng/mL. The intra-assay
coefficient of variation was 3.9%.
2.2.6. Placenta collection
Placenta samples were collected, dissected and frozen within two hours of
delivery. Samples were dissected at four separate sites of the placental disc and stored
by section (basal plate, villous tissue, and chorionic plate) at -80°C until being thawed for
study. Experiments in this study used villous tissue snap frozen within two hours of
delivery and pooled from the four collection sites.
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2.2.7. Quantitative real time PCR
Placenta tissue mRNA was isolated from flash-frozen tissue with the RNeasy Mini
Kit (QIAGEN). Samples were quantified by Nanodrop and all samples had 260:280 and
260:230 ratios greater than 1.75. Two thousand nanograms of RNA was reverse
transcribed with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems)
into cDNA. Quantitative real-time PCR was performed with 20 ng of cDNA, 300 nM of the
forward and reverse primers, and iTaq universal SYBR green mastermix. The PCR
protocol was performed on a 7900HT PCR Machine (ThermoFisher Scientific, Waltham,
MA) beginning with one cycle at 95⁰C for 10 minutes, then 40 cycles of 95⁰C for 15
seconds and 59⁰C for 1 minute, and ended with a dissociation curve analysis. Primers
sequences unique for each target gene were designed with primer BLAST to span exonexon junctions. The geometric mean of PPARα and FATP1 was used as an endogenous
control.
Table 2.1 Primer sequences (human)
Gene
FGF21
FGF21
PPARα
FATP1

Forward
GCTTCGGACTGGTAAACATTG
TGGATCGCTCCACTTTGACC
GGCAAGACAAGCTCAGAAC
AGGTGGTCAGTACATCGGG

Reverse
GGAGTCAAGACATCCAGGTT
GGGCTTCGGACTGGTAAACA
TTATCTATGAAGCAGGAAGCAC
AGAACTCCCCGATTTGGC

2.2.8. Statistical analysis
Data are presented as mean ± standard error. Fasting insulin and HOMA-IR were
logarithmically transformed. Statistical significance was determined by linear regression
analyses or paired student’s t-tests when appropriate. Tests were performed with
significance level α=0.05, and findings considered significant when P<α.

44

2.3. RESULTS
2.3.1. Participants
The study cohort was 29±5 years old at the time of enrollment and was comprised
of participants who self-identified as Caucasian (n=37), black (n=5) and other (n=1). Using
first measured study height and weight (<14 weeks gestation), 14 participants were
overweight (BMI 25-29.9kg/m2) and 29 participants were obese (BMI ≥ 30 kg/m2) (16
within Class I, 7 within Class II, and 6 within Class III). Enrollment weight and BMI were
in close agreement with self-reported pregravid weight documented in the physician office
at the confirmation of pregnancy. Population characteristics are detailed in Table 2.2.
Table 2.2 Participant characteristics
1st Trimester
29.1 (5.0)

Pre-pregnancy

3rd Trimester

p value*

Age at enrollment
Parity (0/1/2/3/4)
20/20/0/2/1
Race
Black
5 (11.6%)
White
37 (86.1%)
Other
1 (2.3%)
BMI Class
Overweight
13
14
2
Obese- Class I
17
16
17
Obese- Class II
8
7
14
Obese- Class III
5
6
10
2
BMI (kg/m )
32.8 (5.4)
33.5 (5.3)
36.6 (4.7)
<0.0001
Weight (kg)
86.8 (14.5)
88.6 (14.5)
96.9 (13.3)
<0.0001
Fat mass (kg)
40.4 (10.5)
41.8 (9.7)
0.04
Percent fat (%)
45.0 (5.4)
42.6 (5.0)
<0.0001
Lean mass (kg)
48.3 (6.1)
55.3 (6.1)
<0.0001
0.002
Fasting glucose (mg/dL)
84.6 (8.0)
81.5 (7.6)
<0.0001
12.4 (7.9)
16.8 (9.3)
Fasting insulin (uIU/mL)
HOMA-IR
2.7 (2.0)
3.4 (2.1)
0.002
Values reported as mean (± standard deviation); *differences between first and third trimesters
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2.3.2. Pattern of FGF21 in human pregnancy
Circulating FGF21 concentrations are highly variable among humans (66). In
fasting serum samples collected from our cohort of healthy women in the first and third
trimesters, FGF21 was highly variable as well. In the first trimester FGF21 concentrations
ranged from 0.035 to 0.256 ng/mL (Figure 2.1A) and there was an even larger degree of
variability observed in the third trimester (range 0.056-0.850 ng/mL, Figure 2.1B). First
trimester FGF21 concentrations showed ten-fold less variance compared to third
trimester concentrations, 0.003 versus 0.033, respectively. FGF21 concentrations were
more than 2-fold higher in the third trimester of pregnancy compared to concentrations
measured in the first trimester, 0.105 vs. 0.248 ng/mL, respectively (Figure 2.1C).
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Figure 2.1 Serum FGF21 concentrations in the first and third trimesters of our study
population. (A) Distribution of FGF21 in the 1st trimester (<16 weeks) (n= 29), (B)
Distribution of FGF21 in the 3rd trimester (35-36 weeks) (n=43), (C) Individual and mean
± SEM serum FGF21 measured across pregnancy, 1st trimester: 0.105 ± 0.01 ng/mL,
3rd trimester: 0.248 ± 0.03 ng/mL, *p<0.0001.
2.3.3. FGF21 is correlated with maternal body size and adiposity throughout
pregnancy

The literature in non-pregnant individuals shows FGF21 is elevated with higher
BMI and, hence, increased adiposity. In this population, FGF21 concentrations were
significantly and positively correlated with maternal BMI in both the first (r=0.48,
p=0.008) and third trimesters (r=0.38, p=0.01) (Figure 2.2A and B). However, FGF21
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was not correlated to body weight at either time point during gestation (p=0.07 and
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Figure 2.2 Serum FGF21 is significantly correlated with maternal body mass index but
not body weight throughout pregnancy. (A) 1st trimester BMI, n=29, r=0.48, p=0.008,
(B) 3rd trimester BMI, n=43, r=0.38, p=0.01, (C) 1st trimester body weight, n=29, r=0.34,
p=0.07, and (D) 3rd trimester body weight, n=43, r=0.19, p=0.23.

FGF21 concentrations were strongly and significantly correlated with maternal
adiposity reported as total fat mass (kg) in both the first and third trimesters (1st
trimester: r=0.51, p=0.005; 3rd trimester: r=0.33, p=0.03) (Figures 2.3A and B).
However, FGF21 concentrations were not significantly correlated with maternal fat
free mass in either trimester (1st trimester: r= -0.02, p=0.92, 3rd trimester: r= -0.14,
p=0.38) (Figures 2.3C and D). Considering FGF21 is strongly correlated with adiposity
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and not body weight or fat free mass, these results suggest that FGF21 regulation
may be more related to energy balance rather than body size or products of
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Figure 2.3 Serum FGF21 is significantly correlated with maternal adiposity throughout
pregnancy. (A) 1st trimester fat mass, n=29, r=0.51, p=0.005, (B) 3rd trimester fat mass,
n=43, r=0.33, p=0.03, (C) 1st trimester fat free mass, n=29, r= -0.02, p=0.92, and (D) 3rd
trimester fat free mass, n=43, r= -0.14, p=0.38.
Maternal BMI prior to pregnancy was significantly correlated with FGF21
concentrations measured during pregnancy, regardless of body weight or composition
changes during gestation. Maternal pregravid BMI was significantly correlated with
FGF21 concentrations in the first trimester (r=0.51, p=0.005) (Figure 2.4A) and third
trimester (r=0.38, p=0.01) (Figures 2.4C). Maternal pregravid body weight also correlated
with first trimester, but not third trimester, FGF21 concentrations (1st: r=0.39, p=0.04; 3rd:
r=0.23, p=0.14) (Figures 2.4B and D).
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Figure 2.4 Serum FGF21 measured during pregnancy is significantly and positively
correlated with pre-pregnancy BMI and body weight. (A) Pregravid BMI and 1st trimester
FGF21 (n=29, r=0.51, p=0.005), (B) pregravid body weight and 1st trimester FGF21
(n=29, r=0.39, p=0.04), (C) pregravid BMI and 3rd trimester FGF21 (n=43, r=0.38,
p=0.01), and (D) pregravid body weight and 3rd trimester FGF21 (n=43, r=0.23, p=0.14).
2.3.4. FGF21 is not correlated with glucose homeostasis in normal pregnancy
FGF21 has been shown to positively correlate with fasting glucose, fasting insulin,
and insulin resistance in animal models and non-pregnant humans (70, 71, 73, 74, 77).
In our healthy population of pregnant women with normal glucose tolerance and maternal
overweight or obesity, there were no significant relationships between FGF21 and fasting
glucose (p=0.55 and 0.10, Figures 2.5A and D respectively), fasting insulin (p=0.18 and
0.48, Figures 2.5B and E respectively), or HOMA-IR (p=0.20 and 0.38, Figures 2.5C and
F respectively) were observed in either the first or third trimesters.
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Figure 2.5 First and third trimester serum FGF21 is not correlated with maternal glucose
homeostasis in early or late pregnancy. (A) 1st trimester glucose and FGF21, n=29,
r=0.12, p=0.55, (B) 1st trimester insulin and FGF21, n=29, r=0.26, p=0.18, (C) 1st trimester
HOMA-IR and FGF21, n=29, r=0.25, p=0.20, (D) 3rd trimester glucose and FGF21, n=42,
r=0.26, p=0.10, (E) 3rd trimester insulin and FGF21, n=42, r=0.11, p=0.48, and (F) 3rd
trimester HOMA-IR and FGF21, n=42, r=0.14, p=0.38.
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2.3.5. Change in glucose, not adiposity, correlates with change in FGF21 across
pregnancy
In an effort to understand if changes in maternal characteristics throughout
gestation may explain the increase in FGF21, we tested for relationships between the
change in FGF21 (absolute and percent) and change in known contributors of FGF21 in
the non-pregnant state, namely adiposity and metabolic status. As expected, body weight,
fat mass, fat free mass, and fasting insulin each increased from the first to the third
trimester while surprisingly, fasting glucose decreased slightly (Table 2.2). Although we
observed significant relationships between body composition, namely adiposity at single
time points, the changes in these parameters across pregnancy were not associated with
the changes in FGF21 concentrations measured across the same time interval (Figures
2.6A-C). However, the change in FGF21 concentrations was significantly and negatively
correlated with the change in fasting glucose (n=29, r= -0.40, p=0.03) (Figure 2.6D).
There was no relationship observed between change in FGF21 and change in insulin or
HOMA-IR (n=29, r= -0.23, p=0.22 and n=29, r= -0.28, p=0.14 respectively) (Figures 2.6E
and F).
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Figure 2.6 Change in FGF21 across pregnancy is correlated with change in maternal
fasting glucose but not change in maternal body size or adiposity. Percent change in
FGF21 from first to third trimester compared to (A) percent change in body weight (n=29,
r=0.12, p=0.52), (B) percent change in fat mass (n=29, r=0.02, p=0.93), (C) percent
change in fat free mass (n=29, r=0.18, p=0.35), (D) percent change in glucose (n=29, r=
-0.40, p=0.03), (E) percent change in insulin (n=29, r= -0.23, p=0.22), and (F) percent
change in HOMA-IR (n=29, r=-0.28, p=0.14).
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2.3.6. The placenta is not a primary source for FGF21 production in pregnancy
FGF21 has been reported to be produced by the human placenta by two separate
laboratories, in one study by ELISA of placenta explant media (79) and two other studies
by qPCR of flash frozen human placenta samples (86, 183). We therefore hypothesized
that the two-fold increase in FGF21 concentrations in the third trimester compared to the
first trimester may originate from the placenta. Despite the three earlier reports of FGF21
production by human placental tissue, we were not able to detect meaningful and
replicable quantities of FGF21 transcript in human placenta by qPCR utilizing two different
sets of primers.
2.4. DISCUSSION
In this study, we describe FGF21 in a healthy pregnant population with pregravid
overweight or obesity and normal glucose tolerance. The three novel observations from
this body of work are that circulating FGF21 measured in fasting conditions was
correlated with maternal body mass index and adiposity before and throughout
pregnancy, FGF21 concentrations increased across pregnancy, and this increase in
FGF21 was not related to change in maternal energy stores but with changes in maternal
glucose concentrations.
The relationship of FGF21, BMI, and adiposity has been well reported in nonpregnant animal models and human populations (65, 70, 72, 75-78, 89). In the current
study, FGF21 concentrations positively correlated with maternal body mass index and
adiposity in pregnant women, not only at the onset of pregnancy but also in both the first
and third trimesters. Considering pregnancy is a time for increased energy deposition in
preparation for postpartum energy demands, e.g. lactation, these findings show the
relationship between FGF21 and adiposity seen in non-pregnant states holds in and
53

across pregnancy. However, it is important to note the individual change in adiposity
across pregnancy did not predict FGF21 concentrations; this finding suggests the
physiological drivers of maternal energy deposition in fat mass are independent of
changes in FGF21.
Notably, we were unable to confirm that high concentrations of FGF21 are present
in individuals with increasing levels of glucose intolerance. Lack of support for this
relationship in our population could be due to insufficient statistical power because we
excluded participants with pregravid maternal diabetes and impaired glucose tolerance in
their first trimester (HbA1c< 6.5%). This exclusion limited the variability in glucose
dysfunction within our cohort despite the large range of maternal BMI. While fasting
insulin and HOMA-IR showed moderate distribution among participants across
pregnancy (see Table 2.2), glucose regulation appeared highly controlled. Indeed, the
percent change in fasting glucose, from the first to third trimester, ranged from -20% to
+9%, with fasting glucose decreasing in two-thirds of the participants. Therefore, our
population had normal glucose tolerance, and there was limited variability in measures of
glucose homeostasis for comparison with FGF21. This explanation is further corroborated
by reports of increased FGF21 in women with gestational diabetes (79, 80), a condition
we did not include in our study. Future studies need to be conducted in pregnant women
with varying degrees of glucose tolerance to further elucidate the changing role of FGF21
in response to maternal glucose homeostasis throughout pregnancy.
We observed FGF21 concentrations were less variable and significantly lower in
the first trimester compared to the third trimester of pregnancy. Given the previous reports
of FGF21 expression in the human placenta, it was reasonable to hypothesize that the
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increase in circulating FGF21 could be attributed to placenta tissue. Following in
extensive qPCR experiments in a subset of term human placentas from our cohort, we
were unable to quantify expression of FGF21. We therefore conclude that the human
placenta is not contributing meaningful amounts of FGF21 into the maternal circulation.
However, because FGF21 correlates with maternal BMI and adiposity, it is logical to
hypothesize that the rise in FGF21 throughout pregnancy can be explained on the bases
of concurrent and variable increase in maternal energy stores. The increase in FGF21
was not found to be correlated with change in body weight or adiposity across pregnancy.
FGF21 has been regularly shown to correlate with glucose homeostasis in nonpregnant and pregnant populations with glucose dysfunction which could be another
possible explanation for the change in FGF21 across pregnancy. Despite the limited
variability of glucose homeostasis within our cohort, we observed a significant negative
correlation between change in FGF21 and change in fasting glucose, implying that the
more FGF21 increased, the more fasting glucose decreased during pregnancy. As seen
at single time points during pregnancy, there was not a significant correlation between
change in insulin or HOMA-IR and change in FGF21 either. The relationship between
FGF21 and glucose regulation in pregnancy merits further investigation as we made
these observations within a healthy population with little variability and the original role of
FGF21 was indeed as a glucose regulator.
Therefore, since the changes in FGF21 were associated with changes in fasting
glucose and not with the changes in body energy stores (i.e. weight or fat mass), we
hypothesize changes in energy status, that is, the maternal diet, which influences both
tissue deposition in tissues and glucose regulation, might be involved. Specifically,
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changes in dietary protein intake can result in changes in glucose regulation, such that
consumption of high protein diets can significantly lower glucose concentrations, while
conversely, diets low in protein raise blood glucose levels (184-187). Indeed, FGF21 has
been shown to be regulated by various dietary states (e.g. fasting, ketogenic diets, amino
acid deprivation, etc.). Most recently, the nutrient-driven responses of FGF21 have been
proposed to be due to protein intake (125, 129). Though our study did not administer a
dietary intervention, naturally occurring variations in protein accretion, protein demand,
and self-selected protein intake within our cohort produced the opportunity to study the
effects of low and high protein availability in pregnancy. In our study, participants are
enrolled and FGF21 measured in the first trimester when classic studies of leucine
kinetics and 15N lysine tracers have demonstrated little to no protein accretion (188, 189).
However, by the end of pregnancy, an approximated 925 grams of protein is deposited
which requires increased estimated daily depositions of 3.6 g/day and 7.2 g/day in the
second and third trimesters respectively (173, 190). Therefore, by the third trimester, we
hypothesize the increased need for protein is achieved by those few individuals who
adequately increase protein intake. This thereby would result in majority of women
consuming a reduced protein diet, having poor regulation of glucose homeostasis
(increased fasting concentrations), and responding by induction of FGF21.
In summary, we observed maternal FGF21 is positively correlated with maternal
body mass index and adiposity before and throughout pregnancy, and FGF21 is likely
responsive to short-term changes in macronutrient balance induced by maternal diet
rather than long-term changes in energy balance reflected in the maternal energy stores.
We propose FGF21 may be a signal of nutrient insufficiency; particularly an insufficiency
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arising from reduced maternal protein intake in pregnancy in the presence of elevated
total intake and subsequent gain in adiposity.

57

CHAPTER 3: FIBROBLAST GROWTH FACTOR 21 IS A PROTEIN
SENSOR IN PREGNANCY
3.1. INTRODUCTION
Diet is the most commonly described regulator of fibroblast growth factor 21
(FGF21). FGF21 concentrations are elevated in response to fasting (66, 115, 122),
ketogenic diets (122), amino acid deprivation or low protein diets (123-129), and
overfeeding (88). However, the novel discovery that FGF21 concentrations in circulation
are robustly increased in states of protein restriction, even while controlling for energy
intake (129), suggest that the elevations in FGF21 induced by ketogenic diets and fasting
are likely due to the coincident reduction of protein in these conditions rather than
ketogenesis or energy restriction itself. Moreover, Solon-Biet et al. completed a study of
>800 mice on 25 various diets and, in support of Laeger’s finding (125), corroborated that
the conflicting reports of FGF21 regulation in the literature are likely due to differences in
nutrient intake. That finding points to dietary protein as the primary regulator of FGF21
(129).
As reported in Chapter 2, serum FGF21 concentrations were significantly lower
and less variable in the first trimester of pregnancy compared to the third trimester in
healthy pregnant women with overweight and obesity. We posit that the increase in
FGF21 across trimesters is due to the increased protein demand of late pregnancy, and
thereby, related to the failure of many pregnant women to increase dietary protein and
consume a reduced protein diet in late pregnancy. In support of this idea, classic studies
employing leucine kinetics and 15N lysine tracers in pregnant women have demonstrated
little to no protein accretion during the first trimester compared to the second and third
trimesters (188, 189). Assuming a typical gestational weight gain of 12.5 kg, including a
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fetus weight of 3.3 kg, a total of 925 grams of protein is expected to be deposited across
pregnancy (173). Whole body potassium studies further estimate for adequate protein
accretion, daily protein depositions double from 8.4 g/day in the second trimester to 16.7
g/day in the third trimester (190). Based on these data, the estimated average
requirement of protein for pregnant women increases from 0.80 grams of protein per
kilogram of body weight per day (g/kg/d) in the first trimester (the same recommendation
for non-pregnant women) to 0.88 g/kg/d in both the second and third trimesters (173).
The recommended dietary allowance is more strict and recommends 1.1 g/kg/d of protein
during the last two trimesters of pregnancy (173). Epidemiological studies of global and
US populations revealed an overall decrease in protein intake over past decades (191);
a finding that likely includes pregnant women. Therefore, considering that women are
likely entering pregnancy eating diets with reduced protein content and that many women
fail to adequately increase protein intake to match protein demands during pregnancy,
we hypothesize that pregnancy is a state of unintentional, self-inflicted protein
insufficiency for many women.
If FGF21 is indeed a sensor of protein intake, we hypothesize FGF21
concentrations will be increased when consuming a low protein diet in pregnancy when
compared to intakes of normal or high protein diets in pregnancy. This hypothesis was
tested in two studies: in 35 pregnant women with self-selected low, normal, or high third
trimester protein intake and in C57BL/6 dams fed a low or normal protein diet throughout
gestation. Finally, inadequate intake of protein by mothers during pregnancy has been
empirically shown to cause fetal growth restriction (192). Because many maternal
hormones have known effects on fetal growth, it is important to understand the effects of
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maternal FGF21 on the fetus, especially if FGF21 is functioning as a nutrient sensor of
low maternal protein intake. We explored this possible role by investigating the impact of
maternal FGF21 on infant size and infant growth throughout the first year of life. We
hypothesized maternal FGF21 measured late in pregnancy (i.e. close to delivery) would
correlate with fetal size at birth and growth in the first year of life.
3.2. MATERIALS AND METHODS
Study 1: Preclinical study of maternal protein intake during pregnancy and FGF21
3.2.1. Animal care and diets
Animal experiments were approved by the Pennington Biomedical Research
Center Institutional Animal Care and Use Committee. Virgin, 8-week old C57BL/6 mice
were purchased from Jackson Laboratory (Bar Harbor, ME) and fed either low or normal
protein diets (by Research Diets, D11092305 and D11092307 respectively). Diets were
designed to be isocaloric, maintaining fat content and altering protein and carbohydrate
content (Table 3.1). By energy, the “normal protein” diet contained 21% protein (as 24%
casein) and the “low protein” diet contained 7% protein (as 8% casein). Animals were
single-housed in a climate-controlled facility with a 12-hour light/dark cycle and ad libitum
access to food and water unless otherwise indicated. Animals were maintained on
standard chow until set up for breeding. Male and female mice were multi-housed (2
females: 1 male) for two dark cycles (approximately 40 hours) to breed and were fed the
female’s respective randomized low or normal protein diet during this time. Females were
then single-housed and the randomized diet (low or normal protein diet) was continued
and measured daily until animals were sacrificed on gestational day 18.5 (first night of
breeding considered 0.5). Mice were sacrificed in the fed state by acute CO2 exposure
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during the mid-light cycle. Blood was collected by cardiac puncture and the uterus was
immediately excised. Each pup and placenta unit were carefully dissected, weighed, and
flash frozen for future analyses, while liver, WAT depots, BAT, and muscle from the dams
were simultaneously collected and also snap frozen. Blood was allowed to clot at room
temperature and serum collected after centrifugation at 3000g.
Table 3.1 Detailed compositions of mouse diets
Ingredient (g)
Casein
L-Cystine
Corn Starch
Maltodextrin 10
Sucrose
Cellulose
Soybean Oil
Lard
Mineral Mix S10022G
Mineral Mix S10022C
Calcium Carbonate
Calcium Phosphate, Dibasic
Potassium Citrate, 1 H20
Potassium Phosphate, Monobasic
Sodium Chloride
Vitamin Mix V10037
Choline Bitrartrate
Protein (gram%)
Carbohydrate (gram%)
Fat (gram%)
Protein (kcal%)
Carbohydrate (kcal%)
Fat (kcal%)
Kcal/gram

Low Protein Diet
(D11092305)
80
1.2
458.3
150
107.1
50
25
75
0
3.5
9.5
4.2
2.5
6.9
2.6
10
2.5
7
73
10
7
71
22
4.1

Normal Protein Diet
(D11092307)
240
3.6
315.2
150
107.1
50
25
75
0
3.5
12.5
0
3.6
5.5
2.6
10
2.5
21
58
10
21
57
22
4.1

3.2.2. FGF21
Fibroblast growth factor 21 was measured in duplicate by sandwich enzyme-linked
immunosorbent assay (ELISA) according to manufacturer instructions for humans
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(RD191108200R, Fibroblast Growth Factor 21 Human ELISA, Biovendor, Brno, Czech
Republic) and mice (RD291108200R, Fibroblast Growth Factor 21 Mouse/Rat ELISA,
Biovendor, Brno, Czech Republic). Human serum was diluted 1:2 (125μL of serum in
125μL of dilution buffer) and murine serum was diluted 1:5 (50μL of serum in 200μL of
dilution buffer) before analysis. The detectable concentration by the human assay is 0.03
ng/mL and mouse assay is 0.04 ng/mL. The intra-assay coefficient of variation was 3.9
for the human assay and 3.0 for the mouse assay.
3.2.3. Quantitative real time PCR
mRNA was isolated from flash-frozen tissue with the RNeasy Mini Kit (QIAGEN)
and was quantified by Nanodrop. All samples had 260:280 and 260:230 ratios greater
than 1.75. Two thousand nanograms of RNA was reverse transcribed to cDNA with the
High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative realtime PCR was performed on 20ng of cDNA for human tissues and 4ng of cDNA for murine
tissues, 300nM of each of forward and reverse primer, and iTaq universal SYBR green
mastermix on a 7900HT PCR Machine (ThermoFisher Scientific, Waltham, MA). The
PCR protocol began with one cycle at 95⁰C for 10 minutes, followed by 40 cycles of 95⁰C
for 15 seconds and 59⁰C for 1 minute, and ended with a dissociation curve analysis.
Primer sequences unique for each target gene were designed with primer BLAST to span
exon-exon junctions. Cyclophilin A was used as the endogenous control for murine
samples and the geometric mean of PPARα and FATP1 was used as an endogenous
control for human samples.

62

Table 3.2 Murine primer sequences
Gene
FGF21
Cyclophilin A

Forward
CAAATCCTGGGTGTCAAAGC
CTTCGAGCTGTTTGCAGACAAAGT

Reverse
CATGGGCTTCAGACTGGTAC
AGATGCCAGGACCTGTATGCT

Table 3.3 Human primer sequences
Gene
KLB
FGFR1
PPARα
FATP1

Forward
GGCTTTGAATGGCAGGATGC
GTCCAGCCCCTGCTATCTCA
GGCAAGACAAGCTCAGAAC
AGGTGGTCAGTACATCGGG

Reverse
CCACAGACTCGGGCTTAAGAA
CCTTTTCAAACTGACCCTTGCC
TTATCTATGAAGCAGGAAGCAC
AGAACTCCCCGATTTGGC

Study 2: Cross-sectional study of maternal protein intake, FGF21 concentrations,
and fetal growth
3.2.4. Study population
Thirty-five pregnant women were included in this ancillary study based on provision
of consent for future use of biospecimens (i.e. blood and/or placenta) as well as data
availability collected from two main studies: the Expecting Success Study (n=54,
NCT01610752) or the MomEE study (n=60, NCT01954342), completed at Pennington
Biomedical Research Center in Baton Rouge, Louisiana. Participants were healthy,
overweight or obese women (BMI ≥ 25kg/m2), aged 18-40 years with a single, viable, first
trimester pregnancy (<14 weeks gestation). For enrollment into this ancillary study,
participants must have been enrolled in a parent study (Expecting Success or MomEE),
provided consent for use of biospecimens in future research, and had archived serum
and data necessary to address study aims collected in the third trimester (35-36 weeks).
Both parent studies and the ancillary study were approved and monitored by the
Pennington Biomedical Research Center Institutional Review Board and all participants
provided verbal and written consent prior to study initiation.
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3.2.5. Clinic assessments
The parent studies enrolled women in the first trimester of pregnancy (<14 weeks
gestation) and study visits for data collection coincided with gestational age to allow for
one assessment visit per trimester, i.e. 1st trimester (<15 weeks gestation) and third
trimester (35-36 weeks gestation). Study visits were conducted in the morning following
an overnight fast and allowed for collection of body weight, body composition, and blood.
All data were obtained in accordance with standard operating procedures of Pennington
Biomedical Research Center to ensure scientific rigor and reproducibility.
3.2.6. Protein intake determination
Protein intake during pregnancy was determined by the Remote Food
Photography Method (RFPM), an objective assessment of dietary intake collected over
5-7 days between 35 and 36 weeks gestation. Briefly, RFPM requires participants to
capture images of their food selection and plate waste within a Smartphone application.
The images are sent to a server in real-time and later analyzed using semi-automated
procedures that rely on both computer automation and human operators (registered
dieticians) from validated methodology (193). The validity of the RFPM has been tested
and procedures are published (194, 195). Utilizing these data, average protein intake was
determined as percent of energy (kilocalories per day), grams per day, and grams per
kilogram of body weight per day.
3.2.7. Protein intake classifications
The Dietary Reference Intake recommendations for protein intake in pregnancy
from the Institute of Medicine are published as total daily intakes, i.e. as grams per day
(g/d) and grams per kilogram of body weight per day (g/kg/d): EAR= +21g/d or 0.88g/kg/d,
RDA= 1.1 g/kg/d (173). We chose to use g/kg/d for classification of protein intake and
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based our upper and lower classification bounds on the recommended EAR and RDA:
participants who reported consuming less than 0.88 g/kg/d of protein were classified as
having low protein intake, 0.88-1.1 g/kg/d were classified as normal protein intake, and
greater than 1.1 g/kg/d as high protein intake.
3.2.8. Infant phenotyping
Infant length was measured by placing the infant on an infant length board with a
built-in centimeter scale, stationary head-board and moveable foot board. Infant body
weight was measured with the infant undressed by electrical infant scale. Head
circumference was measured by a standard measuring tape around the infant’s head. All
measures were repeated in duplicate and averaged. Percentiles were calculated for the
infant measurements considering the gender, date of birth, and date of measurement
according to the World Health Organization growth charts (http://www.cdc.gov/growth
charts/who_charts.htm).
3.2.9. Placenta collection
Placenta samples were collected, dissected and frozen within two hours of
delivery. Prior to dissection, tissue was kept refrigerated or on ice. Samples were
dissected from the placental disc at four separate sites and stored by section (basal plate,
villous tissue, and chorionic plate) at -80°C until being thawed for study (Figure 3.1).
Additionally, gross morphology (photography, placenta shape and cord insertion site),
weight, membrane sample, cord tissue sample and cord blood were collected.
Experiments in this study used snap frozen villous tissue pooled from four sites on the
placenta collected within two hours of delivery.
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Figure 3.1 Illustration of human placenta dissection map
3.2.10.

Statistical analysis

Data are presented as mean ± standard error. To determine statistical significance,
for Aim 1 (investigating protein diet effects on FGF21 concentrations in pregnancy)
students t-test’s, analysis of variance, or linear regression analyses were employed where
appropriate. The PROOF study, which showed for the first time that FGF21 is induced by
low protein feeding in humans, was used for power calculations and sample size
estimates in the current study (196). In PROOF, FGF21 increased by 171.5% in
participants consuming a low protein diet and by 14.8% in participants eating normal
protein diets, giving an observed difference of over 150%. Based on the SD from the
PROOF data (106%), to detect a difference of 150% in FGF21 between diet groups and
ensuring 80% power, nine participants per group were required (Table 3.4). For Aim 2
(investigating the impact of maternal FGF21 on infant size and infant growth throughout
the first year of life), partial correlations were estimated adjusting for gestational age at
delivery, infant gender, and randomization (intervention or control). Tests were performed
with significance level α=0.05, and findings considered significant when P<α.
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Table 3.4 Power Calculations
Power (%)
80
80
80

% Difference FGF21
50
100
150

SD
106
106
106

N Per Group
72
19
9

3.3. RESULTS
3.3.1. In mice, FGF21 is elevated with low protein intake during pregnancy
In serum from C57BL/6 female mice on day 18.5 gestation (Figure 3.2), FGF21
concentrations were 20-fold higher in mice fed low (7%) versus normal (21%) protein
diets throughout gestation (22.760 ± 7.416 ng/mL vs. 1.673 ± 0.176 ng/mL, *p=0.006,
n=5-7).
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Figure 3.2 Serum FGF21 is elevated in states of low protein intake during pregnancy in
mice. Serum FGF21 concentrations from C57BL/6 mice on day 18.5 gestation fed low
(7%) or normal (21%) protein diets, (22.760 ± 7.416 ng/mL vs. 1.673 ± 0.176 ng/mL,
*p=0.006, n=5-7)
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3.3.2. In mice, the liver, not placenta, is the primary source of protein-inducible
FGF21 production in pregnancy
To understand the tissue(s) responsible for the increase in FGF21 during
pregnancy, we measured the expression of FGF21 in placenta and liver of the mice fed
low and normal protein diets. We were unable to identify meaningful and reproducible
levels of FGF21 transcript by qPCR in the placenta in mice which replicates our finding in
pregnant women (Chapter 2). Hepatic FGF21 expression at day 18.5 of gestation was
7.6-fold higher in mice fed a low versus normal protein diet throughout gestation (p=0.002)
(Figure 3.3).
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Figure 3.3 Hepatic FGF21 mRNA expression in pregnant C57BL/6 mice fed a low
versus normal protein diet, relative expression: 9.565 ± 1.86 vs. 1.26 ± 0.39, n=5,
*p<0.01.
3.3.3. Classification of maternal protein intake
To determine whether maternal FGF21 is induced by low protein diets in pregnant
humans, self-reported dietary intake data collected in the third trimester (35-36 weeks
gestation) was used to classify participants as eating low, normal, or high protein diets
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(classification bounds described in Section 3.2.7). The distribution of third trimester
protein intake is shown as percent of total energy and grams per kilogram of body weight
per day (Figure 3.4A and B). The majority of participants (60%, or n=21) reported
consuming a low protein diet which had a mean group protein intake of 0.70 ± 0.12 g/kg/d.
Eight participants (23%) reported consuming a normal protein diet which had a group
mean intake of 0.98 ± 0.09 g/kg/d, and six participants (17%) reported consuming a high
protein diet which had a mean group intake of 1.39 ± 0.20 g/kg/d (Figure 3.4C).
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Figure 3.4 Distribution and classification of third trimester protein intake in study
population. (A) Distribution of protein intake reported as percent of total energy, (B)
Distribution of protein intake reported as grams of protein per kilogram of body weight per
day, (C) Classifications of low (n=21), normal (n=8), and high (n=6) protein intake
calculated as g/kg/d from self-reported third trimester food intake, *p<0.0001.
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3.3.4. FGF21 is elevated with low protein intake during pregnancy in humans
A cross-sectional analysis of FGF21 concentrations in pregnant women according
to their self-reported protein intake relative to dietary recommendations revealed that
FGF21 was significantly higher in those individuals who self-selected a low versus normal
versus high protein diet (Low: 0.302 ± 0.163 ng/mL, Normal: 0.206 ± 0.155 ng/mL, High:
0.133 ± 0.061 ng/mL, p=0.04) (Figure 3.5).

*

Human FGF21 (ng/mL)

0.4
0.3
0.2
0.1
0.0

ein
ein
ein
rot
rot
rot
P
P
P
h
w
al
Lo
rm
Hig
o
N

Figure 3.5 Serum FGF21 is elevated in states of low protein intake during pregnancy in
humans. Serum FGF21 concentrations from humans during 35-36 weeks gestation selfselecting low (0.302 ± 0.163 ng/mL), normal (0.206 ± 0.155 ng/mL) or high (0.133 ± 0.061
ng/mL) protein diets, *p=0.04.
3.3.5. Placental expression of β-Klotho is regulated under variable protein intake
Although the placenta does not appear to synthesize amounts of FGF21
consequential to circulating concentrations, it is possible that the placenta is capable of
responding to the FGF21 of the mother. For example, β-Klotho, the cell surface coreceptor to FGFR1 required for FGF21 signaling (142, 145, 147), has been reported to
be differentially regulated in various states of energy and nutrient balance. In populations
with proposed FGF21-resistance (obesity and diabetes) where FGF21 is found to be
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elevated, β-Klotho expression is decreased in adipose tissue and liver (88). Moreover,
rescuing this reduced expression has been shown to proportionally restore FGF21 action
(197). In a subset of our human study cohort with food intake data as well as archived
placenta samples (n=19), we found no difference in FGFR1 expression and elevated βKlotho expression with reduced maternal protein intake in the third trimester (Figure 3.6),
a state of elevated circulating FGF21 as we previously reported.

However, this trend

failed to reach significance, likely due to high variability and small sample size.
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Figure 3.6 Correlation of human placental (A) FGFR1 and (B) β-Klotho mRNA
expression and maternal protein intake reported between 35-36 weeks gestation (n=19,
p=0.186 and p=0.139 respectively)
3.3.6. Maternal FGF21 influences infant size and growth

In order to further explore the potential role of FGF21 as communicator of
nutrient status between mother, placenta, and fetus, we explored the relationship of
maternal FGF21 and fetal size and growth. For a subset of participants (n=27), infants
of enrolled mothers were also enrolled in our study for collection of anthropometric
assessments through the first year of life. Maternal third trimester FGF21 (an assumed
value for the end of gestation) was found to be negatively correlated with measures
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of infant length at birth (p=0.03, r= -0.45) and length percentile at birth (p=0.02, r= 0.46) (Figures 3.7A and B) such that mothers with high concentrations of FGF21 (and
low protein intake) delivered smaller infants.
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Figure 3.7 Maternal third trimester FGF21 concentration is negatively correlated with
infant length at birth. (A) Maternal 3rd trimester FGF21 and infant birth length (n=27,
p=0.03, r= -0.45) and (B) maternal 3rd trimester FGF21 and infant birth length percentile
(n=27, p=0.02, r= -0.46).
Maternal FGF21 measured in late pregnancy was also found to negatively
correlate with infant growth, i.e. infant anthropometrics collected throughout the first year
of life. Serum FGF21 measured in the third trimester of pregnancy negatively correlated
with infant weight (r= -0.51, p=0.02) (Figure 3.8A), infant length (r= -0.44, p=0.04) (Figure
3.8B), and infant head circumference (r= -0.66, p<0.01) (Figure 3.9A) measured between
4 and 8 weeks of age.
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Figure 3.8 Maternal third trimester FGF21 concentration is negatively correlated with
infant size at 4-8 weeks of age. (A) Maternal 3rd trimester FGF21 and infant weight (n=25,
r= -0.51, p=0.02) and (B) maternal 3rd trimester FGF21 and infant birth length percentile
(n=25, r= -0.44, p=0.04).
Considering head circumference is a robust marker for intrauterine nutritional
sufficiency that can be measured at birth and persists throughout adulthood (198), it was
interesting to find the negative correlation of maternal FGF21 and infant head
circumference and head circumference percentile at 1-2 months of age (cm: p<0.01, r= 0.66, percentile: p=0.03, r= -0.45; Figures 3.9A and B) extended through 6 months of age
(cm: p=0.01, r= -0.53, percentile: p=0.01, r= -0.58, Figures 3.9C and D) and 1 year of life
(cm: p<0.01, r= -0.66, percentile: p<0.01, r= -0.66) (Figures 3.9E and F).
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Figure 3.9 Maternal third trimester FGF21 concentration is negatively correlated with
infant head circumferences through the first year of life. (A) Maternal 3rd trimester FGF21
and infant head circumference (n=25, r= -0.66, p<0.01) and (B) percentile (n=25, r= -0.45,
p=0.03) at 4-8 weeks of age, (C) maternal 3rd trimester FGF21 and infant head
circumference (n=24, r= -0.53, p=0.01) and (D) percentile (n=24, r= -0.58, p=0.01) at 6
months of age, and (E) maternal 3rd trimester FGF21 and infant head circumference
(n=24, r= -0.66, p<0.01) and percentile (n=24, r= -0.66, p<0.01) at 1 year of age.
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3.4. DISCUSSION
In this study, we investigated the role of FGF21 as a novel endocrine signal of
nutrient status in pregnancy. Using cross-sectional analyses in pre-clinical and clinical
studies, the key finding is that maternal FGF21 is induced by low protein intake in
pregnancy. We also observed reduced protein intake correlated with increased β-Klotho
expression in the placenta. Based on the elevated circulating FGF21 and FGF21 coreceptor placenta expression, we hypothesized that FGF21 could exert effects on the
placenta resulting in downstream effects on fetal development. In our investigations of
this mechanism, we found maternal FGF21 measured late in pregnancy was negatively
correlated with fetal size at birth and growth during the first year of life.
The relationship between FGF21 and diet (e.g. fasting (66, 115, 122), ketogenic
diets (122), amino acid deprivation or low protein diets (123-129), and overfeeding (88))
has been well described. Recent studies have demonstrated that FGF21 is robustly and
specifically responsive to protein intake (125, 129). Pregnancy is an intriguing model for
the study of FGF21 biology because of the pregnancy-driven increase in protein demand
(173). In our study, FGF21 concentrations were elevated in response to low protein intake
in pregnancy in both mice and humans. An important and alternative explanation to
consider is the altered carbohydrate content in the low and normal protein diets. While
we attribute the observed induction of FGF21 to the alterations in protein intake, SolonBiet et al. observed that low protein intake coupled with high carbohydrate intake results
in an exacerbated elevation in FGF21 compared to when carbohydrate is held constant.
Therefore, due to the formation of the diets, our study cannot exclude a potential role for
carbohydrate, either independently or in addition to protein. Interestingly, neither mouse
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or human placenta appear to be contributing to this increase in serum FGF21 in the
mother. However, mice showed a robust increase in FGF21 transcript in the liver of
pregnant dams consuming a low protein diet in pregnancy. These findings suggest that,
like non-pregnant models, FGF21 is responding to the nutritional status of the mother with
the liver and without additional sensing from the placenta. It was also intriguing to find βKlotho expression in the human placenta was negatively correlated with maternal protein
intake. Other reports have shown decreased β-Klotho expression in fat and liver in states
of FGF21-resistance (88). However, our findings suggest low maternal protein intake may
contribute to an elevated sensitivity to FGF21 by the placenta by increasing co-receptor
expression. Nevertheless, due to high variability and small sample size, our results failed
to reach significance and the role of the regulation of β-Klotho in communications between
maternal FGF21, placental function, and the fetus requires further investigation.
There is a well established, causative relationship between low maternal protein
intake during pregnancy and fetal growth restriction. However, to our knowledge, FGF21
has yet to be measured in these conditions. Considering our new evidence that FGF21
is elevated with low maternal protein intake in pregnancy, it would be advantageous to
explore if FGF21 could be a clinical test to identify women and infants at risk for low levels
of fetal growth. As detailed in Chapter 1, individuals born small have an increased risk for
chronic disease in adulthood. Identifying a biological marker for detection of growth
restriction during gestation, coupled with proactive intervention, could have long term
health benefits for the infant. In our study, we hypothesized that elevated FGF21 may be
a maternal signal of insufficient fetal growth. Using maternal FGF21 measured in the third
trimester as an assumed indicator of FGF21 concentrations at the end of pregnancy, we
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found an inverse association with infant size at birth (length) and growth in the first year
of life (length, weight, and head circumference). Interestingly, head circumference at birth
and throughout infancy is used as a clinical indicator of intrauterine nutritional sufficiency
as 60-70% of adult head circumference is achieved by the time a fetus is born and 8090% by age two (165). In our study, we observed that head circumference was decreased
in infants of mothers with elevated FGF21 in late pregnancy. This finding further supports
our hypothesis that FGF21 is up regulated in pregnancies that have inadequate maternal
protein intake.
In sum, we have reported maternal FGF21 positively correlates with maternal BMI
and adiposity in pregnancy and negatively correlates with infant size at birth and infant
growth in the first year of life. While these findings can appear contradictory, we propose
FGF21 may be acting as a mediator and/or signal of the Protein Leverage Hypothesis
(PLH). The PLH posits that total energy intake is driven by protein requirement, i.e. when
consuming a low protein diet, an individual will over-consume all macronutrients in order
to satisfy daily protein balance and thereby increasing total energy intake. The PLH
creates a model of elevated energy intake (hyperphagia) and inadequate protein intake.
Indeed, in a randomized controlled trial, Gosby et al. observed an elevation in circulating
FGF21 commensurate with an elevated ad libitum energy intake in humans consuming a
low protein diet (128). Consequently, we propose FGF21 to be a signal of fetal nutrient
insufficiency; particularly an insufficiency arising from reduced maternal protein intake in
pregnancy in the presence of elevated total intake and subsequent gain in adiposity.
Future studies to directly test this proposed role of FGF21 in pregnancy would include
animal studies to, first, establish the PLH in pregnancy with low and adequate protein
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diets during gestation. Furthermore, replicating this experiment in an FGF21 knock out
mouse model would enable direct study of whether the increased energy intake observed
with a low protein diet is FGF21 dependent.
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CHAPTER 4: FIBROBLAST GROWTH FACTOR 21 IS A MEDIATOR OF
PROTEIN LEVERAGE
4.1. INTRODUCTION
The Protein Leverage Hypothesis (PLH) theorizes that total energy intake is driven
by protein requirement, i.e. when consuming a low protein diet, an individual or animal
will over-consume all macronutrients in order to satisfy daily protein balance and thereby
increase total energy intake. This hypothesis was originally proposed by Simpson and
Raubenheimer as a contributor to the obesity epidemic (191). Simpson et al. described
decreased ratios of protein intake to carbohydrate and fat in the common diet in
epidemiological studies (191). Mechanistic studies in rodents and humans have since
demonstrated protein-induced hyperphagia by provision of low protein diets and
assessment of food intake (199, 200). However, the PHL however has not yet been tested
in pregnancy.
Pregnancy is a normal physiological state that demands an increase in the protein
requirement and, as such, without proper dietary modifications to increase protein intake,
pregnancy can lead to an unintentional protein restriction. It is approximated that the 925
grams of protein is deposited during a human pregnancy that requires an increase in
protein deposition of 3.6 g/day and 7.2 g/day in the second and third trimesters
respectively (173, 190). Simpson and others have described changes in the composition
of adult diets globally and found them to be lacking in adequate protein intake (191).
Given changes in the available food sources, we hypothesize that many women
unintentionally consume a reduced protein diet. Pregnancy adds an increased protein
demand and thereby becomes an advantageous model to test the PLH. Our recent finding
that circulating fibroblast growth factor 21 (FGF21) increases throughout pregnancy and
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in concert with acute changes in glucose status could suggest that FGF21 is acting as a
nutrient sensor in pregnancy. It is also plausible that FGF21 is responding specifically to
maternal protein intake, leading us to ask if FGF21 is a mediator of the PLH in pregnancy.
The first goal of our study was to determine whether low protein-induced
hyperphagia (as predicted by the PLH) is present during pregnancy. We hypothesized
pregnant, C57BL/6 mice would have a higher energy intake when fed a low versus normal
protein diet throughout gestation. The second goal of our study was to determine whether
FGF21 serves as a mediator of the PLH. First, as proof of concept, we employed protein
choice experiments with non-pregnant C57BL/6 and FGF21 null mice. We hypothesized
C57BL/6 mice would consume an average protein intake within a set point, while mice
without FGF21 would have erratic protein intake. Second, to investigate the causative
role of FGF21 in protein leverage in pregnancy, we aimed to determine whether low
protein-induced hyperphagia is present in FGF21KO pregnancies. We hypothesized
FGF21KO mice would not differ in energy intake when fed a low protein versus normal
protein diet throughout gestation.
4.2. MATERIALS AND METHODS
4.2.1. Animal care
Female wild type (C57BL/6) and FGF21 knock out (FGF21KO) mice were used in
studies. C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME) and
FGF21KO mice on the C57BL/6 background were provided by Steven Kliewer (University
of Texas Southwestern, Dallas, Texas, USA) (92). For all experiments, animals were
single-housed in a climate-controlled facility with a 12-hour light/dark cycle and allowed
ad libitum access to food and water unless otherwise indicated. All studies were approved
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by the Pennington Biomedical Research Center Institutional Animal Care and Use
Committee.
4.2.2. Effect of low protein diet on food intake in pregnancy
Overview: Eight week old, virgin female C57BL/6 mice (n=12) were bred with
C57BL/6 males and provided a low or normal protein diet throughout gestation. Daily
food intake was measured starting on gestation day (GD) 1.5 until animals were sacrificed
on GD18.5.
Design: Male and female mice were multi-housed (2 females: 1 male) for two dark
cycles to breed (approximately 40 hours). The first night of breeding is considered GD0.5.
Females were randomized to receive either a low (7% protein) or normal (21% protein)
protein diet throughout gestation (Table 4.1). In order to feed the respective randomized
diet throughout pregnancy, diets commenced at the onset of breeding (GD0). Following
breeding, females were single housed on GD1.5 and continued on their randomized diet
(low or normal protein). Body weight was measured weekly and food intake was
measured at the same time daily until animals were sacrificed on GD18.5. Mice were
sacrificed in the fed state by acute CO2 exposure during the mid-light cycle. Blood was
collected by cardiac puncture, allowed to clot at room temperature, and serum collected
after centrifugation at 3000g. Necropsy was performed for collection of liver, WAT depots,
BAT, and muscle from the dam, while simultaneously each pup and placenta unit were
carefully dissected, weighed, and flash frozen.
Diets: Diets were formulated by Research Diets (D11092305 and D11092307
respectively) and were designed to be isocaloric (4.1 kcal/g), maintaining fat content
(22%) and altering protein and carbohydrate content (Table 4.1). By energy, the normal
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protein diet contained 21% protein (as 24% casein) and the “low protein” diet contained
7% protein (as 8% casein).
Table 4.1 Mouse Diet Compositions
Ingredient (g)
Casein
L-Cystine
Corn Starch
Maltodextrin 10
Sucrose
Cellulose
Soybean Oil
Lard
Mineral Mix S10022G
Mineral Mix S10022C
Calcium Carbonate
Calcium Phosphate, Dibasic
Potassium Citrate, 1 H20
Potassium Phosphate, Monobasic
Sodium Chloride
Vitamin Mix V10037
Choline Bitrartrate
Protein (g%)
Carbohydrate (g%)
Fat (g%)
Protein (kcal%)
Carbohydrate (kcal%)
Fat (kcal%)
Kcal/gram

Low Protein Diet
(D11092305)
80
1.2
458.3
150
107.1
50
25
75
0
3.5
9.5
4.2
2.5
6.9
2.6
10
2.5
7
73
10
7
71
22
4.1

Normal Protein Diet
(D11092307)
240
3.6
315.2
150
107.1
50
25
75
0
3.5
12.5
0
3.6
5.5
2.6
10
2.5
21
58
10
21
57
22
4.1

Statistical Analysis: Data are presented as mean ± standard error. At sacrifice,
number of pups were counted for each dam and food intake data were normalized for
(divided by) litter size and reported as grams per day per pup (g/d/pup). For measure of
food intake during “early” and “late” gestation, three day averages of normalized food
intake were calculated using GD3.5-5.5 and GD14.5-16.5 respectively. To measure
elevations in pregnancy-driven food intake, “early” food intake was subtracted from “late”
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food intake. Statistical significance was determined between low and normal protein
groups with unpaired students t-test’s. All tests were performed with significance level
α=0.05, and findings considered significant when P<α.
4.2.3. Role of FGF21 in protein sensing in female mice
Diets: Diets were formulated by Research Diets (D11092301, D11092304, and
D11092303) and were designed to be isocaloric, maintaining fat content (22%) and
altering protein and carbohydrate content (Table 4.2).
Table 4.2 Mouse Diet Compositions
Ingredient (g)
Casein
L-Cystine
Corn Starch
Maltodextrin 10
Sucrose
Cellulose
Soybean Oil
Lard
Mineral Mix S10022C
Calcium Carbonate
Calcium Phosphate, Dibasic
Potassium Citrate, 1 H20
Potassium Phosphate, Monobasic
Sodium Chloride
Vitamin Mix V10037
Choline Bitrartrate
Protein (gram %)
Carbohydrate (gram %)
Fat (gram %)
Protein (kcal%)
Carbohydrate (kcal%)
Fat (kcal%)
Kcal/gram

4% Protein
36% Protein 55% Protein
(D11092301) (D11092304) (D11092303)
50
410
630
0.75
6.15
9.4
485
238
41
150
75
75
107.08
107.08
107.08
50
50
50
25
25
25
75
75
75
3.5
3.5
3.5
8.7
12.2
12.2
5.3
0
0
2.4773
8
8
6.86
0
0
2.59
2.59
2.59
10
10
10
2.5
2.5
2.5
5
36
54
76
42
22
10
10
10
4
36
55
74
42
23
22
22
22
4.15
3.99
3.89
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Overview: Eight week old, virgin C57BL/6 and FGF21KO female mice were
provided a choice of two diets variable in protein content and were allowed to eat ad
libitum. Food was weighed daily and protein intake calculated.
Design: Female C57BL/6 (n=19) and FGF21KO (n=20) mice were single-housed
for 14 days and provided two diets of variable protein content simultaneously, one with
low protein content (4% protein) and another with high protein content (either 36 or 55%
protein) (Table 4.2). Mice were allowed to eat ad libitum. Diet choices were separated by
the water trough and swapped daily to control for side preference. For each diet, food
intake was measured at the same time daily. Mice were sacrificed by acute CO2 exposure
and decapitation at the end of study.
Statistical Analysis: Data are presented as mean ± standard error. To determine
protein intake, each diet was weighed daily. The weights were multiplied by the respective
percent protein content, and these two values were added together to calculate total
grams of protein intake per day. As a measure of protein sensing, two-day averages of
protein intake were calculated for study days 4-10; study days 1-3 were excluded to allow
for acclimation to single-housing and diet change. A logistic model for repeated measures
was constructed with fixed effects for diet composition, mouse type, day, and the
interaction between mouse type and day. The repeated binary response indicated
whether the two-day running average percentage of protein intake was within 20±5%.
The running average was used to help determine if there was day-to-day compensation
for high or low intake. A random mouse effect was included to account for within-animal
correlations over time. For each mouse genotype, probabilities of achieving desired
protein intake (20±5%) across any two-day sequence were estimated from the logistic
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model. Additionally, odds of hitting the target protein range were compared between the
two mouse types using a t-test of the log odds ratio. All tests were performed with
significance level α=0.05, and findings considered significant when P<α.
4.2.4. Role of FGF21 in protein leverage in pregnant mice
To investigate the causative role of FGF21 in protein leverage in pregnancy, the
Effect of low protein diet on food intake in pregnancy experiment was repeated in
FGF21KO mice (See Section 4.2.2 for design and statistical analysis). Briefly, eight week
old, virgin female FGF21KO mice (n=11) were bred with FG21KO males and provided a
low or normal protein diet throughout gestation (Table 4.1). Food intake was measured
daily from gestation day (GD) 1.5 until animals were sacrificed on GD18.5.
4.3. RESULTS
4.3.1. Evidence of protein leverage in pregnancy in C57BL/6 mice
C57BL/6 female mice were fed low or normal protein diets throughout gestation to
determine whether the hyperphagia previously documented with low protein feeding in
male mice (201-204) is present in pregnancy. C57BL/6 mice fed a low protein diet
consumed more throughout gestation compared to mice fed a normal protein diet (Figure
4.1A). However, this elevation in food intake was only significantly higher than those
consuming normal protein diets in late pregnancy (Figures 4.1A and B).
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Figure 4.1 C57BL/6 mice respond to the increased protein requirement of pregnancy with
hyperphagia when fed a low protein diet. (A) Average daily food intake of pregnant
C57BL/6 mice consuming a low (gray, n=5) and normal (black, n=7) protein diet, (B) 3day average food intake of pregnant C57BL/6 mice consuming a low (gray, n=5) and
normal (black, n=7) protein diet in early pregnancy (GD3.5-5.5) and late pregnancy
(GD14.5-16.5), **p=0.009, *p=0.02
4.3.2. FGF21 is required for protein sensing in female mice
C57BL/6 and FGF21KO mice were allowed to eat ad libitum for 14 days from two
diets provided simultaneously; one diet was low in protein content, 4% energy, and the
other diet was high in protein content, 36% or 55% energy. As hypothesized, C57BL/6
mice regulated protein intake. Representative patterns of daily protein intake using three
example C57BL/6 mice are shown in Figure 4.2A. Protein intake oscillated in response
to the protein intake consumed on the previous day. When protein intake is averaged
across the week, each mouse consumed approximately 20% protein. In contrast, daily
oscillations in food intake were not observed in the FGF21KO mice suggesting that these
mice were incapable of regulating daily intake on the basis of protein. As such, FGF21KO
mice consumed the provided diets at random without responding to the protein intake
from the previous day (three example mice, Figure 4.2B).
86

10
ay

9
D

ay

8
D

ay
D

ay

7

6
D

ay

4
D

D

D

ay

ay

10

9
ay

8
D

ay
D

D

ay

7

6
ay
D

ay

0

60

40

20

FGF21KO
C57BL/6
10
9-

9
8-

8
7-

7
6-

5-

4-

6

0
5

Protein intake (% energy)

C

D

D

ay

5

0

20

ay

20

40

5

FGF21KO example
protein intake (%energy)

40

60

D

B

60

4

C57BL/6 example
protein intake (%energy)

A

Study days (average)

Figure 4.2 Female C57BL/6, and not FGF21KO, mice defend certain level of protein
intake. Daily self-selected protein intake of three example (A) C57BL/6 and (B) FGF21KO
mice on study days 4-10, (C) Two-day average self-selected protein intake of C57BL/6
and FGF21KO cohort, n=19-20, red line: estimated protein requirement
To measure protein sensing, we calculated the two-day average of protein intake
(Figure 4.2C) and employed a repeated measures logistic model to determine whether
mice were compensating, or sensing, protein intake from day to day. C57BL/6 mice
averaged 20.7% protein intake across two-day intervals and had a 74% probability of
consuming within 20±5% protein across two-day intervals. FGF21KO mice averaged
30.4% protein intake across two-day intervals and were only 12% likely to consume
20±5% protein across two-day intervals. The difference in probability of the mice to
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choose a diet that provided 20±5% over consecutive 2-day periods was significantly
different (p<.0001).
Table 4.3 Probability from repeated measures logistic model
Bounds

Probability
C57BL6
FGF21 KO
0.74
0.12

20 ± 5%

Odds Ratio

p-value

22.0

<0.0001

4.3.3. FGF21 is a mediator of protein leverage induced hyperphagia during
pregnancy
FGF21KO female mice were fed low or normal protein diets throughout gestation
to determine whether FGF21 is responsible for signaling the hyperphagia observed with
low protein feeding in pregnant C57BL/6 mice (Figure 4.1B). No difference in daily food
intake was observed in pregnant FGF21KO mice fed a low versus normal protein diet
(Figure 4.3A). Moreover, the elevated food intake coinciding with the increased protein
demand in late pregnancy observed in C57BL/6 mice was absent in mice lacking FGF21
(Figures 4.3B and 4.4).
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Figure 4.3 FGF21KO mice fail to respond a low protein diet with hyperphagia in
pregnancy. (A) Average daily food intake of pregnant FGF21KO mice consuming a low
(gray, n=6) and normal (black, n=5) protein diet, (B) 3-day average food intake of pregnant
FGF21KO mice consuming a low (gray, n=6) and normal (black, n=5) protein diet in early
pregnancy (GD3.5-5.5) and late pregnancy (GD14.5-16.5).
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Figure 4.4 C57BL/6, not FGF21KO, pregnant mice exhibit hyperphagia in late pregnancy
when fed a low protein diet. *p=0.006
4.4. DISCUSSION
In this study, we tested the protein leverage hypothesis in pregnancy and
investigated the role of FGF21 as a potential mediator of the protein leverage hypothesis.
Our key findings are that protein leverage can occur during pregnancy in mice and that
FGF21 plays a role in protein sensing in mice. Considered together, we hypothesized
FGF21 could serve as a mediator of the protein leverage hypothesis in pregnancy. We
used FGF21 knock out mice to investigate this mechanism and observed that the lowprotein induced hyperphagia associated with protein leverage in wild type mice was
absent in mice lacking FGF21, suggesting FGF21 is required for protein leverage in
pregnancy.
The Protein Leverage Hypothesis describes a link between protein and energy
intake and specifically demonstrates that protein intake is prioritized over other
macronutrients. This prioritization is consistent with the essential roles that proteins play
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in all cellular processes, as well as the fact that the body does not maintain a protein
reservoir that is rapidly mobilizable for energy analogous to the storage of fat. Protein
deficiency therefore promotes counter regulatory mechanisms leading to adaptive
increases in total energy intake in an effort to restore protein balance (191). For this
reason, total food intake served as the primary outcome variable in our studies to detect
effects of protein leverage. Although the leveraging effect of protein has been
demonstrated in animal models and humans (199, 200), to our knowledge, the protein
leverage hypothesis has not been directly studied in pregnancy. This work warrants
investigation during gestation because diets with reduced protein over long periods would
lead to increased energy intake and excess weight gain resulting in an increased risk for
adverse maternal and fetal outcomes. For example, a study of the Helsinki Birth Cohort
revealed children of overweight and obese mothers have an increased risk of developing
cardiovascular disease, cancer, and type 2 diabetes in adulthood (205). Moreover, a
study from the Dutch Famine Cohort has shown children of mothers consuming a low
protein diet in pregnancy had elevated blood pressure in adulthood, one well known
precursor to cardiovascular disease (38). As, epidemiological studies have shown protein
intake as a percent of total energy consumed has declined across the general population
(191), these considerations make this a question applicable to the pregnant population
consuming a modern-day western diet.
In our study, we found evidence of protein leverage in pregnancy. We observed
an increase in food intake of wild type mice fed low protein diets throughout gestation,
which became more pronounced at the end of pregnancy. A plausible explanation for
this could be the elevated protein requirement in late gestation (173, 190). Perhaps the
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low protein diet that provided 7% of energy from protein was not sufficient to induce a
protein restriction severe enough to elicit the protein leverage response until exacerbated
by the increased protein demand of late gestation. For this reason, we explored the
pattern of food intake across pregnancy, subtracting the three-day average food intake
from early pregnancy from the three-day average food intake from late pregnancy. This
approach revealed a significant increase in food intake with the presumptive increased
protein demand and subsequent amplified protein restriction caused by late gestation.
The recently elucidated role of protein in FGF21 regulation in non-pregnant models
alongside our new evidence of elevated FGF21 in response to low protein intake during
pregnancy (Chapter 3), lead us to investigate the potential role of FGF21 in protein
leverage in pregnancy. First, as proof of concept, we applied this question to a nonpregnant model. Pregnancy undoubtedly presents a unique physiological state which
merits study. However, as protein balance was the primary variable for investigation, the
products of conception, i.e. litter size, would introduce too much variability in altered
pregnancy-driven protein requirement making a non-pregnant rodent model ideal. We
observed FGF21 null mice could not regulate protein intake like wild type mice. These
findings suggest that FGF21 is required for an animal to sense their protein balance and
regulate food intake accordingly. Following this proof of concept, i.e. FGF21 acting as a
protein sensor, we found that the increased food intake that accompanies a low protein
diet in pregnancy was ablated in the absence of FGF21. Taken together, these findings
demonstrate FGF21 to be a protein sensor and necessary for protein leverage during
pregnancy.
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The primary limitation of our study is utilization of a rodent model rather than
conducting a human trial. Studies to test the PLH in humans are complex as the primary
outcome could be influenced by behavior, i.e. energy intake. Research participants with
knowledge of participating in studies aimed to assess food intake are likely to become
more mindful eaters which could convolute results. Indeed, the Simpson Laboratory has
gone to great lengths to alter recipes and disguise food to control for human bias (200).
Also, studies in free-living conditions are problematic because measurement of selfreported food intake, particularly total energy intake, in clinical trials is notoriously
unreliable (206). Finally, studies have repeatedly demonstrated the low protein-induced
hyperphagia predicted by the PLH in male rats and mice (201-204). Taken together,
rodents were a suitable model for initial studies to examine PLH in pregnancy. Moreover,
the availability of FGF21 knock out (FGF21KO) mice allows for investigation of the direct
and causative role of FGF21 in the PLH in pregnancy.
In summary, protein leverage appears to be present in states of protein restriction
during pregnancy in mice. Moreover, FGF21 is required for protein sensing in nonpregnant female mice and is a mediator of the protein leverage hypothesis in pregnant
dams. Future studies are needed to translate these findings into the human population
and to understand the impact on fetal development and offspring growth after birth.
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CHAPTER 5. SUMMARY AND CONCLUSIONS
The overarching goal of this work was to describe for the first time the role of
fibroblast growth factor 21 in pregnancy. In our studies, we first described FGF21 in a
healthy, pregnant population of overweight and obese women and observed that FGF21
was acutely regulated by maternal macronutrient balance. We next studied the role of
protein specifically in FGF21 regulation during pregnancy with pre-clinical (rodent) and
clinical (human) studies. We found that FGF21 was regulated by maternal protein intake
in both mice and humans. Finally, we investigated the potential role that FGF21 might
play under protein imbalance; asking whether FGF21 could be a mediator of the protein
leverage hypothesis in pregnancy. Utilizing FGF21 null mice, we observed that FGF21 is
needed for the low-protein induced hyperphagia associated with protein leverage in
pregnancy. In total, within this body of work, our data reveal FGF21 to be a novel protein
sensor in pregnancy.
In Chapter 2, we conducted a cross-sectional and longitudinal study to describe
FGF21 in a population of healthy pregnant women. Maternal FGF21 concentration was
measured in the first and third trimesters along with measures of body composition and
other circulating factors, e.g. glucose and insulin. Our study showed that the well
described relationships between FGF21 and adiposity are also evident in the pregnant
state, i.e. FGF21 increases as adiposity and BMI increase. However, the longitudinal
study of FGF21 across pregnancy showed that circulating levels of FGF21 are not
responsive to the long-term changes in energy balance (reflected in the maternal fat mass
gain) in pregnancy, but to short-term changes in gluco-regulatory function that reflect
macronutrient balance induced by acute changes in the maternal diet. From these
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studies, we proposed FGF21 to be a signal of nutrient insufficiency; particularly an
insufficiency arising from maternal macronutrient imbalance in pregnancy.
To investigate FGF21 as a signal for fetal nutrient insufficiency in pregnancy, in
Chapter 3 we first asked if the low-protein induced elevation of circulating FGF21
previously shown in male rodents was present during pregnancy. Indeed, we found a
robust increase in serum FGF21 in both mice and human studies with low protein intake
in late gestation. Considering both that maternal diets of low protein result in in utero
growth restriction and maternal FGF21 was elevated with low protein intake in our studies,
we next asked if maternal FGF21 could serve as a marker of fetal nutrient insufficiency.
Indeed, we found maternal FGF21 inversely correlated with the size of offspring at birth
and their growth through the first year of life. Together, these studies demonstrate FGF21
to be a signal of protein restriction and, subsequently, small fetal size and slow infant
growth.
In Chapter 4, we built upon the data presented in Chapter 3 and conducted studies
to implicate FGF21 in a direct and causative role as a protein sensor. Employing protein
choice experiments, mice were allowed to self-regulate protein intake by ad libitum
consumption of two provided diets, one diet low in protein and another high in protein.
Wild type mice exhibited a great affinity for protein sensing and were highly capable of
consuming a combination of both diets which would result in the overall consumption of
their protein requirement, i.e. approximately 20% protein. Repeating this experiment in
FGF21 knockout (FGF21KO) mice showed that mice were not capable of regulating
protein intake without FGF21. These experiments demonstrated FGF21 plays a direct
role in protein sensing in mice.
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Finally, also in Chapter 4, we applied our findings to a model of protein restriction,
the Protein Leverage Hypothesis, for practical testing of this newly elucidated role of
FGF21 in protein sensing. The PHL posits that protein intake is prioritized over other
macronutrients, insofar as an animal or individual will over-consume all macronutrients in
order to attain or near their protein requirement. Evidence of this effect in an experiment
or study is measured by elevated energy intake (hyperphagia) when consuming a low
protein diet. However, to our surprise, the PHL had yet to be tested in pregnancy.
Therefore, in order to test the role of FGF21 in protein leverage in pregnancy we first
needed to replicate, as seen in non-pregnant models, the low-protein induce hyperphagia
characteristic of protein leverage in pregnancy. When fed a low protein diet in late
pregnancy, wild type mice did indeed increase food intake compared to pregnant mice
fed normal protein diets. Next, we repeated this experiment in FGF21KO and as we
hypothesized, the low-protein induce hyperphagia observed in late pregnancy in wild type
mice was absent in mice without FGF21. These experiments serve was direct and
causative evidence for the role of FGF21 as a protein sensor in pregnancy.
In summary, this body of work provides novel and compelling evidence for the role
of FGF21 as a protein sensor in pregnancy. However, future epidemiological and
molecular studies would allow for more translational and mechanistic insights
respectively. As shown in a small sample in Chapter 3, FGF21 may be able to serve as
a biomarker for protein and/or fetal growth restriction during pregnancy. While it is
dangerous and unethical to randomize women to a diet with restricted protein content
during pregnancy, observational studies could be conducted in populations faced with
food scarcity. Indeed, an informative study for further confirmation of the role of FGF21
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as a protein and/or fetal growth restriction biomarker would be measurement of serum
FGF21 and protein balance in these individuals. To further mechanistic insights,
molecular studies of the maternal-placental-fetal unit could better elucidate the effect of
FGF21 when it is elevated in response to protein intake. Considering the placenta
expresses receptors for FGF21, it could be highly informative to measure expression of
placenta nutrient transporters under maternal protein restriction and/or elevated maternal
FGF21. It would also be interesting to measure circulating FGF21 in offspring of
phenotyped pregnancies to determine whether FGF21 overexpression is translated from
mother to infant during protein restricted pregnancies, thereby programming the effect of
protein restriction into offspring whether or not it persists past parturition. Given the
increasing prevalence of obesity in children worldwide and the concomitant reduction in
protein in maternal diets, further exploration of the protein leverage hypothesis in
pregnancy and its role in maternal hyperphagia and gestational weight gain are
warranted.
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